





Elucidating Regulatory Mechanisms of Cardiac CaV1.2 and NaV1.5 Channels 
 



















Submitted in partial fulfillment of the 
requirements for the degree of 
Doctor of Philosophy 
under the Executive Committee 
























































Elucidating Regulatory Mechanisms of Cardiac CaV1.2 and NaV1.5 Channels 
Daniel Dennis Roybal 
 
 In the heart, sodium (Na+) influx via NaV1.5 channels initiates the action potential, and 
calcium (Ca2+) influx via CaV1.2 channels has a key role in excitation-contraction coupling and 
determining the plateau phase of the action potential. Mutations in the genes that encode these 
ion channels or in proteins that modulate them are linked to arrhythmias and cardiomyopathy, 
underscoring the need for characterizing mechanisms of regulation. The work presented in this 
thesis is subdivided into three different chapters, each with a distinct focus on ion channel 
modulation. 
 
The first chapter details our investigation of the functional PKA phosphorylation target 
for β-adrenergic regulation of CaV1.2. Physiologic β-adrenergic activation of PKA during the 
sympathetic “fight or flight” response increases Ca2+ influx through CaV1.2 in cardiomyocytes, 
leading to increased cardiac contractility. The molecular mechanisms of β-adrenergic regulation 
of CaV1.2 in cardiomyocytes are incompletely known, but activation of PKA is required for this 
process. Recent data suggest that β-adrenergic regulation of CaV1.2 does not require any 
combination of PKA phosphorylation sites conserved in human, guinea pig, rabbit, rat, and 
mouse α1C subunits. To test if any non-conserved sites are required for regulation, we generated 
mice with inducible cardiac-specific expression of α1C with mutations at both conserved and non-
conserved predicted PKA phosphorylation sites (35-mutant α1C). Additionally, we created 
 
 
another mouse with inducible cardiac-specific expression of β2 with mutations at predicted PKA 
phosphorylation sites (28-mutant β2B). In each of these mice, β-adrenergic stimulation of Ca2+ 
current was unperturbed. Finally, to test the hypothesis that redundant functional PKA 
phosphorylation sites exist on the α1C subunit and β2 subunit or that several sites confer 
incremental regulation, we crossed the 35-mutant α1C mice with the 28-mutant β2B mice to 
generate offspring expressing both mutant subunits. In these offspring, intact regulation was 
observed. These results provide the definitive answer that phosphorylation of the α1C subunit or 
β2 subunit is not required for β-adrenergic regulation of CaV1.2 in the heart. 
 
In the second chapter, we study the influence of calmodulin and fibroblast growth 
homologous factor (FHF) FGF13 on late Na+ current. Studies in heterologous expression 
systems show that the Ca2+-binding protein calmodulin plays a key role in decreasing late Na+ 
current. The effect of loss of calmodulin binding to NaV1.5 on late Na+ current has yet to be 
resolved in native cardiomyocytes. We created transgenic mice with cardiac-specific expression 
of human NaV1.5 channels with alanine substitutions for the IQ motif (IQ/AA), disrupting 
calmodulin binding to the C-terminus. Surprisingly, we found that the IQ/AA mutation did not 
cause an increase late Na+ current in cardiomyocytes. These findings suggest the existence of 
endogenous protective mechanisms that counteract the increase in late Na+ current that occurs 
with loss of calmodulin binding. We reasoned that FGF13, a known modulator of late Na+ 
current that is endogenously expressed in cardiomyocytes but not HEK cells, might play a 
protective role in limiting late Na+ current. Finally, we coexpressed the IQ/AA mutant NaV1.5 
channel in HEK293 cells with FGF13 and found that FGF13 diminished the late Na+ current 
 
 
compared to cells without FGF13, suggesting that endogenous FHFs may serve to prevent late 
Na+ current in mouse cardiomyocytes.  
 
The third chapter of this thesis focuses on the use of proximity labeling and multiplexed 
quantitative proteomics to define changes in the NaV1.5 macromolecular complex in Duchenne 
muscular dystrophy (DMD), in which the absence of dystrophin predisposes affected individuals 
to arrhythmias and cardiac dysfunction.. Standard methods to characterize macromolecular 
complexes have relied on candidate immunoprecipitation or immunocytochemistry techniques 
that fall short of providing a comprehensive view of the numbers and types of interactors, as well 
as the potential dynamic nature of the interactions that may be perturbed by disease states. To 
provide an inclusive understanding of NaV1.5 macromolecular complexes, we utilize live-cell 
APEX2 proximity labeling in cardiomyocytes. We identify several proximal changes that align 
with the electrophysiological NaV1.5 phenotype of young dystrophin-deficient mice, including a 
decrease in Ptpn3 and Gdp1l and an increase in proteasomal machinery. Whole-cell protein 
expression fold-change results were used to reveal the altered global expression profile and to 
place context behind NaV1.5-proximal changes. Finally, we leveraged the neighborhood-
specificity of proteins at the lateral membrane, intercalated disc, and transverse tubules of 
cardiomyocytes to demonstrate that NaV1.5 channels can traffic to all three membrane 
compartments even in the absence of dystrophin. Thus, the approach of proximity labeling in 
cardiomyocytes from an animal model of human disease offers new insights into molecular 
mechanisms of NaV1.5 dysfunction in DMD and provides a template for similar investigations in 
other cardiac diseases. 
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Ion Channels Facilitate Electrical Signals 
Electrical signals occur in various tissues of the body, mediating cell-cell communication 
for physiologic organ function [1]. The phospholipid bilayer membrane acts as a barrier 
separating ionic species on the inside of the cell from the outside, and this compartmentalization 
allows the establishment of a voltage gradient across the cell membrane. Changes in cellular 
potential are mediated in part by protein complexes called ion channels, which form a 
transmembrane pore and modulate electrical signals by gating ionic flow across the cell 
membrane down their electrochemical concentration gradient. [2]. The ion channels detailed in 
this thesis belong to the voltage-gated ion channel family that open in response to a change in 
voltage across the cell membrane.  
 
Ventricular Action Potential 
Ion channels are essential to the proper function of the heart, where a brief spike in 
membrane potential called the action potential allows the augmentation and propagation of an 
electrical signal, culminating in myocyte and heart tissue contraction. The ventricular action 
potential is defined by four phases, each shaped by depolarizing inward currents and/or 
repolarizing outward currents [3]. The resting potential of a healthy heart is about -85mV. Influx 
of cations from gap junctions at the intercalated disc depolarize the membrane potential to about 
-55mV, resulting in the opening of voltage-gated Na+ channels, including NaV1.5, and initiating 
the phase 0 rapid upstroke of the action potential [4]. After the membrane depolarizes to about 
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+50 mV, Na+ channels rapidly inactivate and voltage gated K+ channels open, initiating the 
phase 1 initial repolarization of the action potential and facilitating outward K+ movement. 
Membrane depolarization also activates L-type voltage-gated Ca2+ channels, including CaV1.2, 
prompting excitation-contraction coupling in the heathy heart. During phase 2, Ca2+ entry 
through voltage activated Ca2+ channels balances K+ efflux, resulting in a plateau in the action 
potential [5]. During phase 3 of the cardiac action potential, voltage- and Ca2+-dependent 
inactivation of L-type voltage-gated Ca2+ channels occurs while K+ channels remain open, 
ensuring a net flow of positive ions out of the cell and a repolarization of the cell. Several K+ 
channels with distinguishing voltage-gating relationships as well as ionic pumps contribute to the 
repolarization and eventual resting potential of the cardiomyocyte during phase 4, resetting the 
process for the next depolarization [3]. 
 
Figure 1. Ventricular action potential. Sequential openings of ion channels and subsequent movement of ions 
down their electrochemical gradients results in the characteristic ventricular action potential waveform. The 
ventricular action potential is divided into four phases based on the specific channels that are predominantly active. 




CaV1.2 Structure and Function 
CaV1.2, encoded by CACNA1C, is an L-type Ca2+ channel (LTCC) that is comprised of a 
pore-forming α1C subunit in complex with several auxiliary subunits including β, α2d, and g [7, 
8]. In the heart, α1C consists of a 240kDa protein that is organized into four homologous domains 
(I–IV), each containing six transmembrane segments (S1–S6) and a pore-forming region 
between S5 and S6 [9]. The alternating positively charged arginine or lysine residues at every 
third or fourth position in the S4 segment of each domain regulate voltage sensitivity. The pore 
region contains the binding sites of L-type Ca2+ channel blocking agents including 
dihydropyridines, phenylalkylamines, and benzothiazepines [10]. There are four subfamilies of 
CaVβs (β1-β4), each with splice variants, encoded by four distinct genes. The guanylate kinase 
(GK) domain and Src-homology 3 (SH3) domain are similar among the CaVβs, whereas the N-
termini, the linker between the SH3 and GK domains, and the C-termini are different [7]. All 
CaVβs increase trafficking of α1C to the plasma membrane and regulate voltage dependence of 
activation. β2 is the predominantly expressed isoform in the adult murine heart [11]. A 
hydrophobic groove on the GK domain interacts with the α-interacting domain (AID) on the α1C 
I-II linker [12, 13].  
 
CaV1.2 is activated at voltages positive to -40 mV and Ca2+ current peaks at 0 to +10 mV. 
On a single-channel level, multiple modes of gating were described for CaV1.2. A null “mode 0” 
is used to describe a state of very rare opening upon depolarization. The term “mode 1” describes 
a mode of low probability and brief activation, while “mode 2” describes a high probability and 
longer-lasting activation [14]. β-adrenergic stimulation of CaV1.2 is postulated to shift the gating 
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mode from mode 0 to mode 1 and mode 2 by shifting a number of channels incapable of 
activation to activable and by increasing the probability of activation for activable channels [15].  
After activation, CaV1.2 undergoes both voltage-dependent inactivation (VDI) as well as Ca2+-
dependent inactivation (CDI). VDI depends on the cytosolic ends of the S6 segments, the I-II 
linker, and the N- and C-termini of the α1C subunit [16]. CDI occurs via calmodulin (CaM), 
which is constitutively bound to the IQ domain on the α1C C-terminus [17]. Following LTCC 
activation, influx of Ca2+ and the subsequent increase in local Ca2+ concentration triggers C-
terminal rearrangements that inhibit channel opening. Upon β-adrenergic stimulation, CDI has 
been suggested to dominate CaV1.2 kinetics over VDI as a result of increased Ca2+ influx leading 
to more CaM binding to Ca2+ [18, 19]. The same domain is required for Ca2+-dependent 
facilitation in which Ca2+ current via CaV1.2 increases as a function of pacing frequency [17].  
 
Mutations that confer gain/loss-of-function properties on CaV1.2 can result in a number 
of human diseases that have cardiac manifestations. Gain-of-function mutations in CACNA1C 
that increase Ca2+ influx that can counteract repolarization, resulting in prolongation of the action 
potential duration and QT interval prolongation. Classically, gain-of-function mutations in 
CACNA1C have been associated with Timothy syndrome where syndactyly, cardiac arrhythmia, 
congenital heart disease, and neurological dysfunction are observed [20, 21]. Slowed voltage-
dependent inactivation and calcium-dependent inactivation of CaV1.2 is the predicted basis of 
Timothy syndrome phenotypes [22]. Loss-of-function mutations in the CaVα1, CaVβ, and CaVα2δ 




Excitation-Contraction (E-C) Coupling 
The initiation of the systolic Ca2+ transient and subsequent contraction of cardiomyocytes 
is dependent on subcellular structures called dyads [24]. Here the sarcoplasmic reticulum (SR) is 
in very close contact with the T-tubule membrane so that the ryanodine receptor (RyR2) on the 
SR is directly adjacent to CaV1.2 on the T-tubule [25, 26]. After CaV1.2 is activated by 
depolarization, Ca2+ current passes through the channel and binds and activates RyR2s [27]. 
RyR2 acts both as a Ca2+ sensor and a Ca2+ channel, releasing stored Ca2+ from the SR and 
amplifying the relatively small Ca2+ signal from CaV1.2 in a process termed Ca2+-induced Ca2+ 
release (CICR). [28]. Increased intracellular Ca2+ binds to troponin on the actin thin filaments 
and induces a conformational change that allows the heads of the myosin thick filament to bind 
to the actin forming crossbridges [29]. Myosin uses the energy stored as adenosine triphosphate 
(ATP) to tilt the myosin head, pulling on the actin filament to create sarcomere shortening and 
cellular contraction. For relaxation to occur, intracellular Ca2+ is removed from the cytosol 
mainly by the SR Ca2+–ATPase (SERCA), which pumps Ca2+ back into the SR, and the 
sarcolemmal Na+/Ca2+ exchanger (NCX), which extrudes Ca2+ from the cell [30]. When 
cytosolic Ca2+ concentration decreases, troponin changes back to its original shape, blocking the 
binding sites on actin and preventing crossbridge formation. 
 
Adrenergic Regulation of the Heart 
The body’s sympathetic nervous system regulates the fight-or-flight response that occurs 
in response to an acute stress event. The sympathetic nervous system is responsible for readying 
the body for action during a perceived harmful event and regulates cardiac function to meet the 
amplified needs of the body [31]. Sympathetic neurohormonal control of cardiac function is 
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exerted by adrenaline and norepinephrine, which is synthesized and released into the 
bloodstream from the adrenal medulla and sympathetic nerve endings [27, 32]. Adrenaline and 
norepinephrine bind to β-adrenergic G protein-coupled receptors on the membrane of 
cardiomyocytes and other cell types. The ensuing activation of adenylyl cyclase by the G-protein 
GSα catalyzes the conversion of cytosolic ATP to cyclic adenosine monophosphate (cAMP). 
cAMP binds to heterotetramer protein kinase A (PKA), resulting in the dissociation of the 
regulatory subunits from the catalytic subunits of PKA, readying the enzyme for phosphorylation 
of target proteins [33].   
 
Figure 2: β-Adrenergic receptor activation and phosphorylation targets relevant to excitation–contraction 
coupling. AC, adenylyl cyclase; ACh, acetylcholine; AKAP, A kinase anchoring protein; β-AR, β-adrenergic 
receptor; M2-Rec, M2-muscarinic receptor; PLB, phospholamban; Reg, PKA regulatory subunit; SR, sarcoplasmic 
reticulum. Figure taken from [27].  
 
In ventricular myocytes, PKA activation leads to the phosphorylation of a number of 
proteins involved in E-C coupling to increase chronotropy (heart rate), inotropy (strength of 
contraction) and lusitropy (extent of relaxation) [27]. The increase in inotropy is critically 
dependent on the amplitude and kinetics of the Ca2+ signal generated by CaV1.2 channels. A 
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PKA-dependent increase in CaV1.2 activity and availability is observed after activation of the β-
adrenergic signaling pathway, although it is unclear which members of the CaV1.2 
macromolecular complex are the phosphorylated targets [34]. Prominent candidates for the PKA 
phosphorylation targets that mediate upregulation of CaV1.2 include the α1C and β2 subunits, 
forming the basis for the investigations conducted in Chapter 1 of this thesis. Another target of 
PKA phosphorylation is phospholamban (Plb), which is a partial inhibitor of SERCA [35]. Plb 
dissociates from SERCA after phosphorylation, relieving its inhibition of SERCA and 
accelerating SR Ca2+ refilling during diastole. Troponin is also phosphorylated, decreasing the 
Ca2+ affinity of myofilaments and accelerating cross-bridge detachment [36]. These events result 
in larger and faster Ca2+ off rate transients, which increases contractile force and accelerates 
relaxation. PKA also phosphorylates RyR2, but the physiological role of this is controversial and 
beyond the scope of this thesis [37-39]. 
 
NaV1.5 Structure and Function 
NaV1.5, encoded by SCN5A, is the primary cardiac isoform of the voltage-gated Na+ 
channel responsible for phase 0 of the ventricular action potential [40]. NaV1.5 consists of a 
pore-forming ~220kDa α subunit in complex with one or two auxiliary ~33kDa β-subunits and 
modulatory proteins that are part of the larger NaV1.5 macromolecular complex [41]. The α-
subunit is comprised of four homologous domains (I–IV), each containing six transmembrane 
segments (S1–S6) and a pore-forming region between S5 and S6 [42, 43]. Voltage-gated 
activation of NaV1.5 is dependent on movement of the S4 segment, which contains positively-
charged amino acids at every third position and serves a voltage-sensing function [4]. In the 
closed state, the negative membrane potential of -70 mV to -90 mV pulls the charges inward by 
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electrostatic force [44, 45]. Activation of the Na+ channels in response to membrane 
depolarization derives from outward movement and rotation of S4, initiating a confirmational 
change that opens the channel pore [46]. Movement of the four S4 segments results in 
conformational changes within the channel that culminate in S6 segments moving to open the 
pore, allowing NaV1.5 to transition to an open state in which Na+ ions can diffuse down their 
electrochemical gradient. [47].  
 
After 1-2 milliseconds, Na+ channels conform into a non-conducting inactivated state 
through a process termed “fast inactivation”. This occurs via an inactivation gate formed by the 
intracellular loop between domains III and IV that binds to and blocks the intracellular side of 
the pore, terminating Na+ influx through NaV1.5 [41]. Mutagenesis studies have revealed a three-
residue hydrophobic IFM (isoleucine, phenylalanine, methionine) motif in III–IV linker that 
interacts with a hydrophobic pocket between domains III and IV [48, 49]. Disruption of this 
mechanism through intracellular perfusion of proteases prevents fast inactivation [50]. 
Additionally, mutations in the Na+ channel C-terminus have been shown to impair inactivation, 
leading to the hypothesis that this region participates in the fast inactivation process [51, 52]. The 
relationship between the III-IV linker and the C-terminus is not clear, but both of these domains 
are required for complete inactivation [53]. The C-terminal domain interacts with CaM as well as 
FGF13, suggesting that these proteins may play a role in the interaction between the channel’s C-
terminus and III-IV linker region  [54, 55]. In addition to fast inactivation, a separate “slow 
inactivation” process occurs on the time scale of hundreds of milliseconds [56]. The molecular 
mechanism of slow inactivation is not as defined as fast inactivation, but structure–function 




Late Na+ Current 
Na+ channel “peak current” represents the maximum inward Na+ current in response to a 
depolarizing stimulus during phase 0 of the cardiac action potential, after which the majority 
transition to an inactivated, nonconducting state. However, some Na+ channels either do not 
inactivate or inactivate and reopen, generating a sustained late Na+ current (INa,L) [59]. INa,L 
persists after phase 0 into phases 1 and 2 where it can lead to prolongation of the plateau phase, 
delayed repolarization, and prolongation of the QT-interval on the ECG [60]. Prolongation of the 
QT interval due to increased INa,L is called long QT syndrome 3 (LQTS3) [3]. Although INa,L 
represents less than 1% of the peak current [61], it has been shown to account for the LQT3 
phenotype in computational and genetically altered mouse models [62, 63]. Failure of Na+ 
channel inactivation during phase 2 or 3 of the cardiac action potential predisposes patients to 
asynchronous early afterdepolarizations (EADs), which result from reactivation of L-type Ca2+ 
channels and lead to premature action potentials [64, 65]. INa,L is also linked to delayed 
afterdepolarizations (DADs) resulting from spontaneous Ca2+ release from the SR and 
subsequent increase in depolarizing currents via the NCX [66]. 
 
Even amongst LQT3 patients, heterogeneity in rate-dependence has been observed, and 
investigations have revealed divergent mechanisms of INa,L generation. Multi-modal composition 
of Na+ current is separated into three distinct gating modalities: transient (peak current), bursts, 
and late scattered openings [67]. Channel bursting describes a mode of gating characterized by 
persistent long-lasting channel openings [61]. This mode has been studied using the ΔKPQ 
(1505-1507del) deletion in the intracellular III-IV loop and, in heterologous expression systems, 
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modal transitions of INa,L from ΔKPQ channels is an inversely dependent on slower pacing 
frequencies [68]. Indeed, LQT3 patients with the ΔKPQ are at higher risk for arrhythmias at rest 
[69, 70]. Late scattered openings are individual openings that are shorter-lasting than burst 
openings. Computational modeling of the S1904L mutation on the C-terminal region provided 
evidence that channel reopening arises due to a deficiency in slow inactivation, keeping channels 
in fast inactivated states from which they can reopen [52]. The multi-modal composition of the 
INa,L may allow for pharmacological targeting of specific gating mode specific modulation. 
 
Disruption of several NaV1.5-interacting proteins have been reported to have a functional 
effect on INa,L. CaM binds to the IQ region on the NaV1.5 C-terminal domain and, although 
effects of CaM on steady-state inactivation have been debated [54, 71], investigation on 
mutations in the IQ region on the C-terminus have shown an increase in INa,L in heterologous 
expression systems [72, 73]. Likewise, mutations that affect the binding of FGF13 to the NaV1.5 
C-terminus increase INa,L, leading to arrhythmias [74]. Recently, evidence was reported 
supporting the hypothesis that CaM and FGF13 limit INa,L by stabilizing an interaction between 
the channel's CTD and III-IV linker region [75]. In HEK293 cells, mutations in α-syntrophin 
caused ~1.5-fold increase in peak Na+ current and ~2.5-fold increase in INa,L [76]. Mutants of 
caveolin-3, which is a member of the dystrophin-glycoprotein complex along with α-syntrophin, 
were found in long-QT syndrome patients and showed an increase INa,L [77, 78]. Finally, 
enzymatic regulation of INa,L was described in results showing increased INa,L after PKA 
phosphorylation of NaV1.5 channels with a long QT-associated mutation in the C-terminus [79]. 
These results exemplify the complex network of INa,L modulatory factors and underscore the 
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importance of elucidating their mechanisms in native cardiomyocytes where all regulatory 
components are expressed.  
 
Considerable efforts are currently being made in the generation of drugs that selectively 
target INa,L over peak Na+ current. In the late 1980’s, results of the CAST trial, whose goal was to 
assess the antiarrhythmic efficacy of Na+ channel blockers, showed that Na+ channel blockers 
increased mortality compared to placebo [80, 81]. This led to wide therapeutic discontinuation of 
use due, in part, to the inability of many Na+ channel blockers to discriminate between peak Na+ 
current and INa,L. Several drugs such as flecainide and lidocaine have demonstrated clinical 
usefulness, but only display a 2.9 to 5-fold and 2.7-fold selectivity for INa,L compared to peak 
Na+ current, respectively [82]. Ranolazine, on the other hand, displays a 9 to 38-fold selectivity 
for INa,L and may prove beneficial for LQT3 patients in reducing action potential duration 
prolongation and suppressing the development of EADs [83].  
 
NaV1.5 Macromolecular Complexes 
NaV1.5 interacts with several proteins that have been shown to modulate Na+ current 
density, activation and inactivation kinetics, and INa,L [84]. Association of these proteins with 
NaV1.5 is required for normal physiological function of NaV1.5. Interestingly, many of the 
interacting proteins are specifically localized to subcellular regions of the cardiomyocytes, 
namely the intercalated disc and the lateral membrane. This has led to the hypothesis that two or 
more separate “pools” of NaV1.5 macromolecular complexes exist in the cardiomyocyte with 




The intercalated disc is a highly orchestrated cellular domain where several 
multicomponent complexes facilitate intercellular communication and cell excitability [86]. It is 
traditionally divided into three major complexes: gap junctions, desmosomes, and adherens 
junctions. Gap junctions, composed principally of connexin-43, connects the cytoplasm of 
adjacent cardiomyocytes to provide a pathway for passage of ions and small molecules between 
cardiomyocytes [87, 88]. Desmosomes and adherens junctions provide mechanical coupling 
between two cells by anchoring the actin cytoskeleton and intermediate filaments, respectively, 
to enhance the strength and stability of the myocardium [89, 90]. Although initial classification 
divided the different intercalated disc structures, recent studies have demonstrated interplay 
between complexes [91-93]. The additional integration of NaV1.5 into complexes at the 
intercalated disc has been suggested through studies that show modulation of NaV1.5 expression 
or function by ankyrin-G [94, 95], plakophilin-2 [96, 97], desmoglein-2 [98], desmoplakin [99], 
and connexin-43 [100, 101], although many of these studies do not demonstrate direct 
interaction. Taken together, these results support the idea of the molecular interaction network at 
the intercalated disc as a single functional unit to control the cardiac excitability, electric 
coupling, and intercellular adhesion. 
 
The second pool of NaV1.5 channels has been described outside the intercalated disc 
domain at the lateral membrane and the T-tubules [102]. NaV1.5 expression at the lateral 
membrane is influenced by the dystrophin-glycoprotein complex (DGC) and the PDZ-binding 
motif of NaV1.5 comprising its last three C-terminal amino acids Ser, Ile, and Val (SIV motif). 
Syntrophin, containing a PDZ domain, acts as an adaptor protein between the SIV motif of 
NaV1.5 and dystrophin, and the stability of NaV1.5 at the lateral membrane has been shown to 
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depend on this interaction [103, 104]. Recently, investigations using mice expressing NaV1.5 
lacking the SIV motif (ΔSIV) and syntrophin knockdown mice showed a reduction, but not 
abolition, of NaV1.5 at the lateral membrane [105]. This indicates the presence of a 
subpopulation of NaV1.5 at the lateral membrane whose expression is independent of DGC 
expression, a hypothesis that has been supported by single-molecule localization microscopy in 
dystrophin-deficient Dmdmdx mice [106]. 
 
The reason for the different pools of NaV1.5 at the lateral membrane and intercalated disc 
continues to be a subject of investigation. Macropatch cell-attached patch clamp methodology 
has been employed to show that the Na+ current recorded in the lateral membrane of cardiac 
myocytes is of smaller amplitude than the current recorded at the intercalated disc [107, 108]. 
Steady-state inactivation was left-shifted in Na+ recordings at the intercalated disc, suggesting 
that Na+ channels in this region may be primarily responsible for action potential upstroke of a 
ventricular myocyte. Optical measurements in in isolated Langendorff-perfused hearts from 
ΔSIV mice, where NaV1.5 expression is specifically decreased from the lateral membrane, have 
shown that ventricular conduction velocity was preferentially decreased in the transversal 
direction, indicating a role for this subpopulation in anisotropy of ventricular conduction [104]. 
These results support the conclusion that region-specific interactions in NaV1.5 macromolecular 
complexes confer different biophysical properties to NaV1.5. 
 
Proximity Proteomics and TMT Mass Spectrometry Analysis 
Specialized biological processes and reactions are compartmentalized into subcellular 
regions and are exerted through protein-protein interactions. Protein functions often correlate 
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with their subcellular interactions with a multi-protein macromolecular complex. Identification 
of protein interactions in these complexes and their alterations after a perturbation— such as 
activation of a pathway or in a disease state— is essential for understanding mechanisms that 
underlie intricate cellular processes. Affinity purification of a protein of interest followed by 
identification of direct and indirect interactors by mass spectrometry has been a widely-used 
approach, but this can be challenging when recovering structures or molecules that are difficult 
to solubilize or easily dissociate after purification [109, 110]. Moreover, even when purification 
techniques are modified to preserve interactions, such as with the use of chemical cross-linkers, 
the number of false positive interactions can increase. Overall, an approach that can identify all 
proteins within spatially resolved and potentially weakly interacting multicomponent complexes 
is needed to characterize protein interaction networks. 
 
Most recently, proximity labeling has emerged as a biochemical approach to bypass the 
requirement of maintaining protein-protein interactions after solubilization [111, 112]. This 
method involves expression of an enzyme that catalyzes the covalent transfer of biotin onto 
endogenous proteins that are within a restricted spatial distance from the enzyme. Fusing the 
enzyme to a protein of interest allows specific localization to a subcellular compartment and 
proximity labeling is initiated in intact cells and tissues where protein complexes are maintained. 
Once labeled, the integrity of interactions does not need to be maintained and the biotinylated 
proteins can then be processed using strict lysis and washing steps followed by purification using 
streptavidin. Streptavidin-purified proteins are subsequently identified and quantified by mass 
spectrometry. Two classes of enzymes have been developed for proximity labeling: biotin 
protein ligases such as BioID [112] and TurboID [113], and peroxidases such as APEX2 [114]. 
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While biotin ligases are useful in their ease of use, the speed of labeling using APEX2 presents 
an advantage when investigating dynamic processes. For example, APEX2 fusion to G-protein 
coupled receptors allowed parallel time-resolved quantitative analysis of thousands of protein-
protein integrations, revealing insights on proteins involved in activation and internalization of 
these receptors [115].  
 
Figure 3. Illustration of peroxidase-catalyzed proximity labeling (APEX). A protein of interest (X) is 
expressed as a fusion protein with an engineered version of a plant ascorbate peroxidase (APEX2). In the 
presence of biotin-tyramide (biotin-phenol) and hydrogen peroxide (H2O2), free radicals of biotin-tyramide are 
formed. They react with surface-exposed tyrosine residues of interacting or neighboring proteins within the 
labeling radius and form covalent biotin adducts (“Bio,” black). Labeling occurs within a radius of about 20 nm 
around the APEX2 module. Proteins outside of the labeling radius are not conjugated to biotin-tyramide. Adapted 
from [116]. 
 
Mass spectrometry can detect and quantify thousands of proteins from a sample of 
proteins and is a powerful tool when coupled with proximity labeling techniques. In particular, 
multiplexed proteomics using tandem mass tag (TMT) labeling allows robust analysis of several 
samples representing various conditions or replicates at the same time by tagging proteins from a 
sample with unique isobaric tags [117]. Some past proximity labeling studies have relied on 
label-free quantification, which is based on running multiple samples subsequently and usually 
16 
 
uses MS1 signal quantification [118, 119]. The requirement for multiple runs, therefore, can 
reduce throughput and introduce variation in results. TMT labeling on the other hand allows all 
tagged samples to be pooled and analyzed in a single mass spectrometry experiment so that 
relative abundances of thousands of proteins from up to 16 different samples are measured in a 
highly reproducible manner. Furthermore, quantification by SPS MS3 rather than applying 
conventional tandem mass spectrometry (MS2) has the advantage of reducing signal ratio 
distortion and improving the accuracy of peptide quantification [120]. To be sure, proximity 
proteomics coupled with TMT labeling and SPS MS3 is an approach that is well-equipped to 
rigorously quantify changes in macromolecular complexes between multiple conditions.  
 
Duchenne Muscular Dystrophy 
Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder caused by a loss-
of-function mutation in the dystrophin gene [121]. Dystrophin is part of the large multimeric 
dystrophin-glycoprotein complex (DGC). The DGC is located in the sarcolemma and acts as a 
mechanical link between the actin cytoskeleton, the muscle membrane, and the extracellular 
matrix. Disruption of this complex leads to membrane fragility, making muscle cells susceptible 
to contraction-induced damage. As the disease progresses, regenerative processes are not able to 
compensate for the ongoing muscle damage, leading to progressive degeneration of myocytes 
and formation of fibrosis, resulting in muscle weakness [122]. DMD manifests as proximal 
weakness in the leg, shoulder, and pelvic girdle muscles and symptoms associated with cardiac 
defects can be masked by progressive muscle weakness and reduced physical activity. Cardiac 
involvement is evident after about 10 years of age and ubiquitous by 18 [123, 124]. 
Electrocardiographic abnormalities are first manifested, followed by progressive fibrosis 
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throughout the ventricular wall, a loss of contractility, and heart failure. With life expectancy 
estimated at about 25 years of age, the most common direct cause of death DMD is respiratory 
failure with the next leading cause of death being cardiac-related conditions such as heart failure 
brought on by dilated cardiomyopathy [125]. 
 
The Dmdmdx mouse model, which has a total loss of functional dystrophin from the 
muscle tissue, has been used for decades for the majority of DMD research [126]. Ventricular 
cardiomyocytes isolated from Dmdmdx mice exhibit a number of characteristics that reveal 
insights on the clinical phenotype of DMD patients. These include a fragile plasma membrane 
[127, 128], a disorganized microtubule cytoskeleton [129-131], impaired Ca2+ handling [132, 
133], and a shift toward a more oxidative intracellular and mitochondrial redox state [134, 135]. 
The precise mechanisms leading to increased cell death and fibrosis are unclear, but augmented 
Ca2+ influx from membrane tears and stretch-activated channels are hypothesized to contribute to 
excessive mitochondrial Ca2+ uptake as well as increased Ca2+-sensitive PKC phosphorylation of 
NAD(P)H oxidase [136, 137]. These events lead to abnormally high intracellular levels of 
reactive oxygen species and initiate necrotic and apoptotic processes that culminate in cell death 
and the development of cardiac fibrosis. Additionally, in Dmdmdx mouse models it has been 
shown that loss of dystrophin leads to a decrease in Na+ current, which is a known risk factor for 
arrhythmias and sudden cardiac death [102, 103]. It is currently unclear whether this disfunction 
is due to loss or redistribution of NaV1.5 channels, or from changes in the NaV1.5 
macromolecular complex. Indeed, a combination of loss of Na+ current and myocardial fibrosis 
may result in a markedly disturbed cardiac conduction and greatly increase the risk for 




There are three primary components to my dissertation. My first aim is to determine 
whether PKA phosphorylation of CaV1.2 α1C and β2 subunits is required for β-adrenergic 
regulation of CaV1.2 in heart. Prior studies have indicated that conserved PKA phosphorylation 
sites on α1C and several sites on β2 are not necessary for regulation. This led to several 
hypotheses including that redundant regulation sites exist between subunits or that α1C and β2 
subunits are not the functional phosphorylation target. To test this, we generated two 
doxycycline-inducible transgenic mice, one expressing α1C with mutations at 35 intracellular 
predicted PKA phosphorylation sites and one expressing β2 with mutations at 28 predicted PKA 
phosphorylation sites. We then cross these two mice to generate offspring that express both 
mutant subunits. We investigate the integrity of β-adrenergic regulation of CaV1.2 in all these 
models to provide the definitive answer about whether PKA phosphorylation of any α1C or β2 
residues is necessary.  
 
In my second aim, I focus on the effects of two auxiliary proteins—CaM and FGF13—on 
the function of NaV1.5 expressed in cardiomyocytes. I hypothesized that, as in HEK cells, loss of 
CaM binding to voltage-gated Na+ channels in cardiac cells will lead to increased INa,L. 
Transgenic mice were generated with inducible expression of IQ/AA NaV1.5, a Na+ channel 
harboring two mutated residues in the known CaM binding site. We found that IQ/AA did not 
increase Na+ late current, indicating that endogenous protective mechanisms exist in 
cardiomyocytes that may be absent in HEK cells. Finally, we coexpressed the IQ/AA mutant 





My third aim is to identify alterations in the early stages of DMD, in which the absence 
of dystrophin predisposes affected individuals to arrhythmias and cardiac dysfunction. Here I 
posit that loss of dystrophin alters the macromolecular complexes of NaV1.5 channels leading to 
changes in its electrophysiological properties. To provide a comprehensive understanding of the 
NaV1.5 macromolecular complexes, we utilized the proximity labeling method by APEX2 to 
identify the interactome of NaV1.5 in cardiomyocytes. We compared changes in the NaV1.5 
interactome to changes in the entire dystrophin-deficient Dmdmdx myocyte proteome in control 
and young Dmdmdx mice hearts, with the goal of precisely defining how DMD modifies the 
NaV1.5 interactome to predispose to heart failure and arrhythmias. Finally, we leveraged the 
neighborhood-specificity of proteins at the lateral membrane, intercalated disk, and T-tubules to 




Materials and Methods 
Mouse Models 
All transgenic mice were generated through the CUMC Shared Research Facilities 
Transgenic Mouse core. Plasmids used for pronuclear DNA microinjection were created in the 
laboratory. V5-TurboID-NaV1.5 knock-in mice were generated by Cyagen. Both male and 
female mice were used in all experiments. The number of mice was always greater than three per 
genotype.  
 
pWT α1C, GFP–WT-β2B, 35-α mutant, 28-β mutant, and 35-α X 28-β 
Transgenic constructs were generated by fusing rabbit α1C cDNA or human β2B cDNA to 
the modified murine α-myosin heavy chain (α-MHC) tetracycline-inducible-promoter vector. A 
3× Flag epitope was ligated in-frame to the N terminus of α1C. The α1C subunit was engineered to 
be dihydropyridine (DHP)-insensitive with the substitutions T1066Y and Q1070M [138, 139]. 
GFP was ligated to the N terminus of β2B. In the background of the the pWT α1C and GFP–WT-
β2B, the 35-α mutant and the 28-β mutant cDNA were generated by site-directed mutagenesis. 
We replaced 51 residues in rabbit α1C with alanine at 35 potential phospho-regulatory domains in 
the 35-mutant α1C construct, and replaced 37 residues with alanine at 28 putative phospho-
regulatory domains of β2B. We excluded those sites that were predicted to be extracellular or 
within the plasma membrane. Transgenic mice with non-targeted insertion of these tetracycline-
regulated cDNAs were bred with α-MHC, doxycycline-regulated, codon-optimized reverse 
transcriptional transactivator (rtTA) mice (obtained via the Mutant Mouse Resource and 




pWT NaV1.5, IQ/AA, F1759A, V5-APEX2-NaV1.5, and V5-APEX2-NaV1.5-Dmdmdx 
The pWT, IQ/AA, F1759A, and V5-APEX2-NaV1.5 lines were generated by fusing 
human heart Na+ channel α-subunit cDNA (hH1) to the modified murine α-MHC tetracycline-
inducible-promoter vector. SCN5A was engineered to be either TTX sensitive by inserting a 
C374Y mutation or lidocaine-resistant by insertion a F1759A mutation. For IQ/AA mice, 
Ala/Ala was substituted at position IQ1908-1909. A 3× FLAG epitope was ligated in-frame to 
the N-terminus. The V5 epitope and APEX2 cDNA, created by gene synthesis, were conjugated 
to the N-terminus of human heart Na+ channel α-subunit. These mice, in a B6CBA/F2 hybrid 
background, were bred with cardiac-specific rtTA mice in a FVB/N background, obtained via 
Mutant Mouse Resource & Research Center, to generate doxycycline-inducible transgenic mice. 
To create V5-APEX2-NaV1.5-Dmdmdx mice, the V5-APEX2-NaV1.5 double transgenic mice 
were crossed with female Dmdmdx mice (Jackson Laboratories, Stock 001801). Male mice were 
used in all V5-APEX2-NaV1.5-Dmdmdx experiments since dystrophin is X-linked. 
 
V5-TurboID-NaV1.5 
The V5-TurboID-NaV1.5 knock-in model was generated by Cyagen. The “Kozak-MG-
HA tag-G-HA tag-G-HA tag-TurboID-V5 tag” (V5-TurboID) was created by gene synthesis and 
inserted upstream of the ATG start codon, which is in 2 of the Scn5a gene located on mouse 
chromosome 9. The targeting vector included homology arms generated by PCR using BAC 
clone RP23-386N9 or RP23-198L19 with V5-TruboID and a Neo cassette flanked by SDA (self-
deletion anchor) sites. DTA was used for negative selection. The targeting construct was 
electroporated into ES cells. Positive clones were identified by PCR and confirmed by Southern 
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blotting. Five clones were injected in C57BL/6N blastocysts, and chimeras were crossed to 
C57BL/6 mice. Heterozygous mice were bred to produce homozygous offspring.  
 
Biochemistry/Molecular Biology  
Isolation of adult cardiac myocytes 
Mice ventricular myocytes were isolated by enzymatic digestion using a Langendorff 
perfusion apparatus as described [140]. Cardiomyocytes were isolated from 8–12-week-old non-
transgenic and transgenic mice. Only non-contracting rod-shaped cells with clear striations were 
used for electrophysiology studies. 
 
Proximity labeling biotinylation 
Isolated ventricular cardiomyocytes were incubated in labelling solution with 0.5 mM 
biotin-phenol (Iris-biotech) for 30 min. For some experiments, during the final 10 min of 
incubation, 1 μM isoproterenol (Sigma I5627) was added. To initiate labelling, H2O2 (Sigma 
H1009) was added to a final concentration of 1 mM for 1 min. Exactly 1 min after 
H2O2 treatment, the cells were washed three times with cold quenching solution containing 
10 mM sodium ascorbate (VWR 95035-692), 5 mM Trolox (Sigma 238813) and 10 mM sodium 
azide (Sigma S2002). After cells were harvested by centrifugation, the quenching solution was 
aspirated, and the pellet was flash-frozen and stored at –80 °C until streptavidin pull-down. 
The cells were lysed with a hand-held tip homogenizer in a solution containing 50 mM Tris 
(tris(hydroxymethyl)aminomethane), 150 mM NaCl, 10 mM EGTA, 10 mM EDTA, 1% Triton 
X-100 (v/v), 0.1% SDS (w/v), 10 mM sodium ascorbate, 5 mM Trolox and 10 mM sodium 
azide, phosphatase inhibitors (Sigma 4906845001), protease inhibitors (Sigma 4693159001), 
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calpain inhibitor I (Sigma A6185) and calpain inhibitor II (Sigma A6060). Biotin labelling of the 
samples was confirmed after size fractionation of proteins on SDS–polyacrylamide gel 
electrophoresis (PAGE), transfer to nitrocellulose membranes, and probing with streptavidin-
conjugated horseradish peroxidase (HRP) (Thermofisher, S911, lot number 1711896, 
0.6 mg ml−1). The response to isoproterenol was assessed by immunoblotting with an anti-
phospho-Pln (Ser16/Thr17) antibody (Cell Signaling, number 8496, lot number 1; 1/1,000 
dilution). Biotinylated proteins were bound to streptavidin magnetic beads (Thermo Fisher 
Scientific 88817), and the beads were washed three times with a solution containing 4 M urea, 
0.5% SDS (w/v) and 100 mM sodium phosphate pH 8. Proteins were size-separated on SDS–
PAGE, transferred to nitrocellulose membranes, and probed with anti-V5 antibody 
(Thermofisher, R960-25; 1/5,000 dilution), a custom-made anti-FGF13 antibody, and an anti-
CaM antibody (Millipore Sigma, 05-173). 
 
Immunoprecipitations 
Cardiomyocytes were lysed with a hand-held tip homogenizer in a 1% (v/v) Triton X-100 
buffer containing 50 mM Tris-HCl (pH 7.4) 150 mM NaCl, 10 mM EDTA, 10 mM EGTA and 
0.01 mM calpain inhibitor I, 0.01 mM calpain inhibitor II, and complete protease inhibitors (1 
per 7 ml, Roche). The lysates were incubated on ice for 30 min and centrifuged at 14,000 r.p.m 
at 4 °C for 10 min; supernatants were then collected. Anti-Flag antibody (Sigma, F7425, lot 
number 078M4886V) immunoprecipitations were performed overnight in a lysis buffer 
consisting of 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.25%-1% Triton X-100 (v/v), 10 mM 
EDTA, 10 mM EGTA, 0.01 mM calpain inhibitor I, 0.01 mM calpain inhibitor II, and complete 
protease inhibitors (1 per 7 ml). Antibody–protein complexes were collected using protein-A-
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conjugated agarose (Amersham) for 2 h, followed by three washes in lysis buffer. Proteins were 
size-separated by SDS, transferred to nitrocellulose membranes and probed with HRP-
conjugated anti-Flag antibody (Sigma, A8592), a custom-made anti-β-antibody and HRP-
conjugated secondary goat anti-rabbit antibody. Detection of luminescence was performed with a 
charge-coupled-device (CCD) camera (Carestream Imaging). 
 
Immunofluorescence  
Isolated cardiomyocytes from V5-APEX2-NaV1.5 were first exposed to biotin-phenol 
and H2O2 as described above. After quenching, the cells were fixed for 15 min in 4% 
paraformaldehyde, washed with glycine/phosphate-buffered saline (PBS) twice, treated with 
0.1% Triton X-100 (v/v) in PBS (PBST) for 5 min, and blocked with 3% bovine serum albumin 
(BSA; w/v) in PBS for 1 h. Indirect immunofluorescence was performed using 1/500 dilutions of 
anti-V5 antibody (Thermo Fisher, R960-25), 1/200 dilutions of Alexa594-labelled goat anti-
mouse antibody (Thermo Fisher, A11032, lot 2069816) and 1/800 dilutions of streptavidin–
Alexa Fluor 488 conjugate (Thermo Fisher, S32354, lot 1719656). Images were acquired using a 
confocal microscope. 
 
Processing biotinylated proteins for mass spectromentry 
Proteins were precipitated with trichloroacetic acid (TCA; MilliporeSigma, T9159) and 
then centrifuged at 21,130g at 4°C for 10 minutes. The pellet was washed with –20°C cold 
acetone (MilliporeSigma, 650501), vortexed, and centrifuged at 21,130g at 4°C for 10 minutes. 
Following centrifugation, acetone was aspirated and the pellet was acetone washed again 3 more 
times. After the last washing step, the pellet was resuspended in: 8M urea, 100 mM sodium 
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phosphate (pH 8), 100 mM NH4HCO3, and 1% SDS (w/v) and was rotated at room temperature 
until fully dissolved. Resuspended proteins were centrifuged at 21,130g at room temperature for 
10 minutes, and the cleared supernatant was transferred to a new microcentrifuge tube. To reduce 
disulfides, 10 mM TCEP-HCl (Thermo Fisher Scientific, PG82089) in Milli-Q water titrated to 
pH 7.5 with NaOH was added. To alkylate free Cys, freshly prepared 400 mM iodoacetamide 
(Thermo Fisher Scientific, 90034) stock solution in 50 mM ammonium bicarbonate was added to 
the supernatant to a final concentration of 20 mM, immediately vortexed, and incubated in the 
dark for 25 minutes at room temperature. After alkylation, freshly prepared DTT (dithiothreitol) 
stock solution was added to 50 mM final concentration to quench alkylation. Water was added to 
each sample to reach a final concentration of 4 M urea and 0.5% (w/v) of SDS. 
A 100 μl suspension equivalent per sample of streptavidin magnetic beads was washed twice 
with a solution containing 4 M urea, 0.5% SDS (w/v) and 100 mM sodium phosphate pH 8, and 
was added to each 1 mg of protein sample, diluting each sample with an equal amount of water 
to reach a final concentration of 2 M urea, 0.25% SDS (w/v), 50 mM sodium phosphate pH 8 
during pull-down. The tubes were rotated overnight at 4 °C. Following streptavidin pull-down, 
the magnetic beads were washed three times with a solution containing 4 M urea, 0.5% SDS 
(w/v), 100 mM sodium phosphate pH 8, and three times with the same buffer without SDS. The 
beads were transferred to new tubes for the last wash step. Before final pulldown of the beads for 





Quantitative real-time polymerase chain reaction (qRT-PCR)  
PCR was performed using Applied Biosystems StepOne Plus PT-PCR system and 
inventoried following inventoried primers: human NaV1.5 Hs00165693_m1; mouse NaV1.5 
Mm01342518_m1; mouse NaV1.6 Mm00488110_m1; mouse NaV1.8 Mm00501467_m1; 
mouse GAPDH Mm99999915_g1. PCR was performed, in triplicate, for 40 cycles with 
automated detection of crossing threshold.  
 
Tandem Mass Tag Labeling and Mass Spectrometry Analysis 
On-bead digestion and TMT labelling 
On-bead digestion, TMT labeling, and mass spectrometry analysis were performed by 
Drs. Marian Kalocsay, Robyn Eisert, and Gary Bradshaw. Liquid reagents used were of high-
performance liquid chromatography (HPLC) quality grade. Washed beads were resuspended in 
50 μl of 200 mM 3-[4-(2-hydroxyethyl)-piperazin-1-yl]propane-1-sulfonic acid (EPPS) buffer 
pH 8.5, 2% acetonitrile (v/v) with 1 μl of LysC stock solution (2 mg ml−1, Wako), vortexed 
briefly and incubated at 37 °C for 3 h. Then, 50 μl of trypsin stock (Promega V5111) diluted 
1/100 (v/v) in 200 mM EPPS pH 8.5 was added. After mixing, digests were incubated at 37 °C 
overnight and beads were magnetically removed. Peptides were directly labelled after digest. For 
this, acetonitrile was added to a concentration of 30% (v/v) and peptides were labelled with TMT 
10-plex or 11-plex reagents (Thermo Fisher Scientific 90406 and A34807) for 1 h. Reactions 
were quenched with hydroxylamine at a final concentration of 0.3% (v/v) for 15 min, and 1% of 
labelled peptides were analysed for efficiency of label incorporation and relative ratios by mass 
spectrometry. After quenching, peptide solutions were acidified with formic acid, trifluoroacetic 
acid (TFA) was added to a concentration of 0.1%, and peptides were desalted and fractionated by 
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high pH reversed phase chromatography (Thermo Fisher Scientific 84868). After loading of 
labelled peptides onto preconditioned columns and a single wash with water, excess 
unincorporated TMT label was removed by washing reversed phase columns once with 0.1% 
trimethylamine (TEA) buffer containing 5% acetonitrile. Samples were fractionated under 
alkaline conditions into 12 fractions with increasing concentrations of acetonitrile: 10%, 12.5%, 
15%, 17.5%, 20%, 25%, 30%, 35%, 40%, 50%, 65% and 80%. Fractions 1 and 7, 2 and 8, 3 and 
9, 4 and 10, 5 and 11, and 6 and 12 were pooled to obtain 6 final pooled fractions for subsequent 
analysis. Pooled fractions were dried to completion and further purified and desalted by acidic 
C18 solid phase extraction (StageTip). Labelled peptides were finally resuspended in 1% formic 
acid (v/v) and 3% acetonitrile (v/v). 
 
Mass spectrometry analysis 
Data collection followed a MultiNotch MS3 TMT method using an Orbitrap Lumos mass 
spectrometer coupled to a Proxeon EASY-nLC 1200 liquid chromatography system (both 
Thermo Fisher Scientific). The capillary column used was packed with C18 resin (length 35 cm, 
inner diameter 75 μm, matrix 2.6 μm Accucore (Thermo Fisher Scientific)). Peptides of each 
fraction were separated for 4 h over acidic acetonitrile gradients by liquid chromatography 
before mass-spectrometry analysis. The scan sequence started with an MS1 scan (Orbitrap 
analysis; resolution 120,000; mass range 400−1,400 Th). MS2 analysis followed collision-
induced dissociation (CID; CID energy = 35) with a maximum ion-injection time of 150–300 ms 
and an isolation window of 0.4 m/z. In order to obtain quantitative information, we fragmented 
MS3 precursors by high-energy collision-induced dissociation (HCD) and analysed the fragments 
in the Orbitrap at a resolution of 50,000 at 200 Th.  
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Peptides were searched with a SEQUEST (v.28, rev. 12)-based software against a size-
sorted forward and reverse database of the Mus musculus proteome (Uniprot 07/2014) with 
added common contaminant proteins. For this, spectra were first converted to mzXML. Searches 
were performed using a mass tolerance of 20 p.p.m. for precursors and a fragment-ion tolerance 
of 0.9 Da. For the searches, a maximum of two missed cleavages per peptide was allowed. We 
searched dynamically for oxidized methionine residues (+15.9949 Da) and, where indicated, for 
phospho-modification of serine, threonine and tyrosine residues (+79.9663 Da). We applied a 
target decoy database strategy and set a false discovery rate (FDR) of 1% for peptide–spectrum 
matches following filtering by linear discriminant analysis (LDA). The FDR for final collapsed 
proteins was 1%. We calibrated MS1 data post-search and performed searches again. We used a 
modified version of the Ascore algorithm to quantify the confidence assignment of 
phosphorylation sites. Phosphorylation localized to particular residues required Ascore values of 
more than 13 (P ≤ 0.05) for confident localization. Quantitative information on peptides was 
derived from MS3 scans. Quant tables were generated requiring an MS2 isolation specificity of 
more than 70% for each peptide and a sum of TMT signal-to-noise (s/n) ratios of more than 200 
over all channels for any given peptide; the tables were exported to Excel and processed further 
therein. Details of the TMT intensity quantification method and further search parameters were 
described previously. Proteomics raw data and search results were deposited in the PRIDE 
archive and can be accessed under ProteomeXchange accession nunbers PXD014499, 
PXD014500 and PXD014501. 
 
The relative summed TMT s/n ratios for proteins between two experimental conditions 
(referred to as ‘enriched’) were calculated from the sum of TMT s/n ratios for all peptides 
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quantified of a given protein. For enrichment of Gene Ontology (GO) terms, the BINGO package 
in Cytoscape was used. Scaled quantification data were subjected to two-way clustering (JMP 
software package) and changes in enrichment were analysed using Graphpad Prism 8 (Graphpad 
Software). Statistical significance was determined by multiple t-tests without correction for 
multiple comparisons and α = 0.05. 
 
Cellular Electrophysiology  
Whole Cell Patch Clamp  
Patch clamp experiments were performed by Dr. Alexander Katchman, Dr. Sergey 
Zakharov, and Daniel Roybal. Experiments were performed at room temperature. Membrane 
currents from non-contracting rod-shaped cells with clear striations were measured by the whole-
cell patch-clamp method using a MultiClamp 700B amplifier or Axopath200B amplifier and 
pCLAMP 10.7 software. The pipette resistance was 1-3 MΩ for Ca2+ recordings and 0.4-1.0 MΩ 
for Na+ recordings. Capacitance transients and series resistance were compensated. Voltage was 
corrected for liquid junction potential (-10 mV) during analysis. Leak currents were subtracted 
by a P/4 protocol. The parameters of voltage-dependent activation were obtained using a 
modified Boltzmann distribution: I(V) = Gmax × (V − Erev)/[1 + exp(V − V50)/Vc)], where I(V) is 
the peak current, Gmax is the maximal conductance, Erev is the reversal potential, V50 is the 
midpoint, and Vc is the slope factor. 
 
For studies of Ca2+ recordings from pWT α1C, 35-α mutant, 28-β mutant, and 35-α X 28-β 
cardiomyocytes, the pipette solution contained 40 mM CsCl, 80 mM cesium gluconate, 10 mM 
1,2-bis(o-aminophenoxy)ethane-N,N,N′, N′-tetraacetic acid (BAPTA), 1 mM MgCl2, 4 mM Mg-
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ATP, 2 mM CaCl2 and 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 
adjusted to pH 7.2 with CsOH. After the isolated cardiomyocytes were dialyzed and adequately 
buffered with 10 mM BAPTA in the internal solution, cells were superfused with 140 mM 
tetraethylammonium chloride (TEA-Cl), 1.8 mM CaCl2, 1 mM MgCl2, 10 mM glucose and 10 
mM HEPES, adjusted to pH 7.4 with CsOH. To measure peak currents, we held the cell 
membrane potential at −50 mV and stepped it to +0 mV for 350 ms every 10 s. To evaluate the 
current–voltage (I–V) relationship in cardiomyocytes, we repeated the same protocol with steps 
between −40 mV and +60 mV in 10-mV increments. Nisoldipine (Santa Cruz) was stored 
protected from light at −20 °C as 3 mM stock in ethanol. The final dilution of nisoldipine to 300 
nM was in the extracellular recording solution immediately before the experiment. Isoproterenol 
(Sigma I5627) and forskolin (Santa Cruz) were prepared daily and diluted in extracellular 
solution. 
 
For studies of Ca2+ recordings from transfected 35-α mutant, 28-β mutant, and Rad in 
HEK293T cells, we implemented the perforated whole-cell patch-clamp technique in order to 
minimize current run-down and preserve the intracellular milieu. Amphotericin B (Sigma 
A9528) was initially dissolved in DMSO (20 mg ml-1) and used in the pipette solution at a final 
concentration of 200 μg ml-1. The tip of the pipette was filled with amphotericin-free solution 
containing 80 mM caesium gluconate, 40 mM CsCl, 10 mM HEPES, 10 mM BAPTA, 1 mM 
MgCl2 and 1 mM Mg-ATP, pH adjusted to 7.2 with CsOH. The pipette was backfilled with 125 
mM CsCl, 10 mM HEPES, 4 mM CaCl2, 1 mM MgCl2 pH 7.2 and CsOH containing 
amphotericin at 200 μg ml-1. The external solution contained 130 mM tetraethylammonium 
methanesulfonate, 10 mM HEPES, 1 mM MgCl2, 10 mM (with Rad expression) or 2 mM 
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(without Rad expression) BaCl2, 5 mM glucose. For experiments with HEK293T cells, in 
addition to step protocols, we used a ramp protocol with a 200-ms voltage ramp from −60 mV to 
+60 mV (0.6 V s-1) applied every 10 s to monitor the I–V relationship. Cells were selected on the 
basis of co-transfection of a vector containing GFP in the absence of Rad, or of a vector 
containing GFP-conjugated Rad.  
 
For studies of pWT NaV1.5, IQ/AA, F1759A, and V5-APEX2-NaV1.5, the pipette 
solution contained 3 mM NaCl, 20 mM CsCl, 115 mM CsF, 10 mM HEPES, and 10 mM 
BAPTA (pH 7.4) titrated with CsOH. For measurement of peak Na+ current, the extracellular 
solution contained 3 mM NaCl, 142 mM TEA-Cl, 10 mM HEPES, 1 mM MgCl2, 0.25 mM 
CaCl2, and 5 mM glucose (pH 7.4) titrated with CsOH. Peak transient currents in the F1759A 
mice were measured with 5 mM Na+ in both intracellular and extracellular solutions (need to 
change int or ext sol to 3 or 5). Peak transient currents were measured by stepping the voltage 
from a holding potential of –110 mV to –30 mV. Peak transient currents for steady state 
activation were determined by stepping the voltage from a holding potential of–110mV to +5 
mV in increments of 5 mV. For V5-APEX2-NaV1.5 cardiomyocytes, steady-state inactivation 
was measured by stepping from a holding potential of-120 mV in increment of 5 mV to voltages 
from -110 mV to +5 mV for 100 ms, following step to -40 mV for 30 ms. For late current 
analysis of pWT NaV1.5, IQ/AA, and F1759A cardiomyocytes, the bath solution contained 100 
mM NaCl, 45 mM TEA-Cl, 10 mM HEPES, 1 mM MgCl2, 0.25 mM CaCl2, and 5 mM glucose 
(pH 7.4) titrated with CsOH. To determine late current, the cell membrane potential was held at 
–110 mM and stepped to –30 mV for 190 ms in the absence and in the presence of TTX (40 μM; 
nontransgenic and F1759A mice) or ranolazine (50 μM; pWT NaV1.5 and IQ/AA mice). The 
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mean value of the current during the last 10 ms of the 190-ms pulse was measured. The 
difference of these values was used as a measure of late Na+ current and later normalized to cell 
capacitance. The mean value of the late current was also normalized to the peak Na+ current for 
each cell. For the cardiomyocytes isolated from F1759A mice, the fraction of transgenic current 
was assessed by applying 3 mM lidocaine. For these cardiomyocytes, the fraction of transgenic 
current was assessed by applying 20 nM TTX, which inhibits all mutant channels (IC50 < 1 nM) 
but has no effect on endogenous, nontransgenic channels. The current-voltage relationship of 
transgenic Na+ currents for the pWT and IQ/AA cardiomyocytes were quantified as the 
difference between no TTX and 20 nM TTX across a range of voltages, from a holding potential 
of –110 mV to 0 mV. 
 
Multichannel analysis of late Na+ current 
Multichannel analysis was performed by Drs. Nourdine Chakouri and Manu Ben-Johny. 
Multichannel records were obtained in the on-cell configuration with either HEK293 cells or in 
cardiomyocytes. The pipette contained (in mM): 140 NaCl, 10 HEPES, and 0.5 CaCl2 at 300 
mOsm adjusted with tetraethylammonium methanesulfonate, and pH 7.4 adjusted with 
tetraethylammonium hydroxide. To zero membrane potential, the bath contained (in mM): 132 
K+-glutamate, 5 KCl, 5 NaCl, 3 MgCl, 2 EGTA, 10 glucose, and 20 HEPES at 300 mOsm 
adjusted with glucose, and pH 7.4 adjusted with NaOH. Data were acquired at room temperature 
using the integrating mode of an Axopatch 200A amplifier (Axon Instruments, Molecular 
Devices). Patch pipettes (3–10 MΩ) were pulled from ultra-thick–walled borosilicate glass 
(BF200-116-10; Sutter Instruments) using horizontal puller (P-97, Sutter Instruments), fire 
polished with a microforge (Narishige), and coated with Sylgard (Dow Corning). Elementary 
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currents were low-pass filtered at 2 kHz with a 4-pole Bessel filter and digitized at 200 kHz with 
an ITC-18 unit (Instrutech), controlled by custom MATLAB software (Mathworks). For each 
pulse, we obtained P/8 leak pulses. Following leak subtraction, the unitary current for each patch 
was estimated using an amplitude histogram. Each stochastic trace was subsequently idealized. 
The ensemble average from 50 to 100 stochastic traces was computed for each patch and 
normalized to the peak current. The average late current for each patch (Rpersist) was computed as 
















Chapter 1: Investigation of the Requirement of PKA 


























In the heart, Ca2+ influx through CaV1.2 is an essential signal that initiates excitation-
contraction (E-C) coupling, regulates cardiac excitability, and shapes the ventricular action 
potential [141, 142]. Physiologic β-adrenergic activation of PKA during the sympathetic “fight 
or flight” response increases Ca2+ influx through CaV1.2 in cardiomyocytes, leading to increased 
cardiac contractility [15] Although PKA activation is established as a fundamental process in the 
initiation of increased E-C coupling, the functional target phosphorylation site(s) that lead to 
CaV1.2 activation are unknown. My aim is to definitively determine whether phosphorylation of 
the pore-forming α1C subunit and the accessory β2 subunit are essential for β-adrenergic 
regulation of Ca2+ influx in the heart. 
 
The long-standing dogma is that CaVα or CaVβ subunits are the functional PKA 
phosphorylation targets, although the data have been contradictory and controversial. Early 
reports suggested that Ser1928 on α1C is the sole regulatory site [143, 144]. Studies in 
heterologous expression systems showed that Ala substitution of Ser1928 prevented upregulation 
of CaV1.2 [145] but, when this concept was tested in ventricular myocytes, it was shown that 
adrenergic regulation of CaV1.2 was unperturbed [146, 147]. After phosphorylation of Ser1928 
was shown to be non-essential for β-adrenergic regulation of CaV1.2 in cardiomyocytes, 
phosphorylation of Ser1700 and Thr1704 was proposed [148, 149]. By generating transgenic 
mice expressing α1C subunits with Ala-substitutions of Ser1700 and Thr1704, our lab showed 
that phosphorylation of these sites is unnecessary for β-adrenergic upregulation of CaV1.2 as 
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transgenic Ca2+ channels were still regulated by β-adrenergic receptor agonist isoproterenol and 
adenylyl cyclase activator forskolin [150]. Confusion on the relevance of these sites persisted 
after Fu et al. generated knock-in mice expressing mutant Ser1700 and Thr1704 and 
demonstrated the requirement of these sites for CaV1.2 upregulation [151]. They based their 
conclusion upon an unconventional metric: the difference in absolute current amplitude rather 
than the fold-increase after isoproterenol, which is the standard analysis. Their metric is valid 
only if the density of Ca2+ channels at the surface was unchanged, yet CaV1.2 membrane 
expression and basal Ca2+ currents were substantially reduced. Poomvanicha et al. subsequently 
created S1700A/T1704A knock-in mice and concluded that isoproterenol stimulated Ca2+ current 
in the control and mutant S1700A/T1704A cardiomyocytes to the same extent [152]. 
Furthermore, Poomvanicha et al. recalculated the data from Fu et al. and showed that in both 
groups’ knock-in mice, the β-adrenergic stimulation for wild-type and mutant channels were 
equivalent.  
 
Further complicating the search is the prospect of the CaVβ subunit as the functional PKA 
phosphorylation target. β2 is the predominant CaVβ in the heart [153, 154]. Phosphorylation sites 
on the β2 subunit have been demonstrated in vivo and in vitro on Ser459, Ser478 and Ser479 
[155-157].  Subsequently, phosphorylation of β2a at these sites was shown to be unnecessary for 
CaV1.2 upregulation in the heart by Miriyala et al. through the generation of an adenovirus 
encoding a mutated β2a in which the 3 confirmed PKA phosphorylation sites were substituted 
with Ala [158]. Additionally, this group investigated the relationship between basal CaV1.2 
current and capacity for regulation to better define the functional reserve for PKA modulation. 
They described an inverse relationship between the degree of channel modulation and basal 
37 
 
current density in both guinea pig and rat cells. Overexpression of β2a, which uniquely increases 
single channel open probability, increased basal current amplitude to a larger degree than cells 
overexpressing other β subunits and exhibited the weakest β-adrenergic modulation. Later, 
Brandmayr et al. created a knock-in mouse expressing a β2 subunit truncated prior to the putative 
phosphorylation sites [159]. These mice displayed normal PKA modulation of CaV1.2. 
Brandmayr et al. also recognized the possibility that PKA simultaneously phosphorylates sites at 
the CaVβ2 and the α1C subunits, rationalizing that phosphorylation of each site could contribute a 
small amount to the overall regulation. To test this, they crossed the truncated β2 mice with mice 
that expressed mutated α1C at Ser1928. These mutations did not affect the β-adrenergic response 
of CaV1.2. Taken together, the prior studies demonstrated that the functional target of PKA in the 
CaV1.2 macromolecular complex was unknown.  
 
1.2 Experimental Design and Approach 
Full reconstitution of the β-adrenergic receptor signaling pathway in heterologous 
expression systems remains an unmet challenge that limits robust investigation [34]. Several 
controversies have arisen from attempts to reproduce reconstitution efforts, with no universally 
accepted results [160]. To study β-adrenergic regulation of CaV1.2 in native cardiomyocytes, a 
system is needed that allows the testing of multiple mutated sites and limits levels of mutant 
protein expression. Knock-in mice are considered the gold standard, but they are time-consuming 
and expensive to generate, and a phenotype of heart failure or death during perinatal period may 
preclude studies at later stages of development [151, 161]. Adenoviruses have been used to 
express CaV1.2 subunits in cardiomyocytes, but these cardiomyocytes need to be cultured for 
extended period, potentially inducing dedifferentiation. Additionally, the large size of the α1C 
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insert is a limiting factor in the efficiency of knock-in and viral transduction methods. To 
circumvent previous problems that have limited progress in the field, our lab developed an 
approach of expressing doxycycline-inducible, tissue-specific rabbit α1C. The rabbit isoform was 
chosen due to the previously observed enhancement of CaV1.2 in cardiomyocytes virally infected 
with rabbit α1C [146]. Inducibility and tissue specificity were achieved by generating transgenic 
mice expressing the cDNA of rabbit α1C ligated behind 7 tandem tetO sequences [162]. tetO-α1C 
mice were crossed to transgenic mice expressing rtTA controlled by the cardiac-specific α-MHC 
promoter (Figure 1C). The bitransgenic tetracycline-regulated system enables acute expression 
of transgenic α1C in the heart only when both transgenes and doxycycline are present. By acutely 
tuning transgene expression through feeding mice with doxycycline for 1-2 days, this approach 
limits overexpression of α1C to preserve hormonal regulation of CaV1.2 and limit chronic effects 
secondary to altered expression [163].  
 
Using this newly developed approach, our lab generated transgenic mice with inducible 
cardiomyocyte-specific expression of an N-terminal 3xFLAG-epitope–tagged DHP-resistant 
rabbit α1C designated pseudo-wild-type (“pWT”). DHP-resistance was used to distinguish 
transgenic from endogenous Ca2+ channels. A concentration of 300 nM nisoldipine blocked 
>98% of heterologously expressed WT CaV1.2 current in tsA-201 cells, but only blocked 34.6% 
of DHP-insensitive α1C [150]. In cardiomyocytes isolated from nontransgenic mice, 300 nM 
nisoldipine inhibited about 92.4% of peak CaV1.2 current. In the pWT background, our lab 
previously created transgenic mice (“22-mutant”) expressing CaV1.2 with Ala substitutions of all 
conserved, previously not studied consensus PKA phosphorylation sites (17 mutations), and sites 
previously shown to be not required for β-adrenergic stimulation of CaV1.2 (rabbit Ser1517, 
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Ser1575, Ser1700, Thr1704, and Ser1928). Sites were only chosen if conserved in rabbit, rat, 
mouse, guinea pig, or human isoforms of CaV1.2 α1C. In the cardiomyocytes isolated from 22-
mutant transgenic mice, isoproterenol increased nisoldipine-resistant peak to a near-identical 
fold-change as the isoproterenol-induced augmentation of nisoldipine-resistant current in pWT 
cardiomyocytes [164]. 
 
Additionally, we reasoned that the functional PKA phosphorylation site exists on the 
CaVβ subunit.  Our lab recently published results showing that the AID motif on α1C is required 
for the high-affinity interaction between α1C and β subunits [165]. We showed that when the AID 
motif is mutated, the β-less CaVα subunits were completely refractory to PKA activation, 
suggesting that CaVβ or an associated protein is the functional PKA phosphorylation target. It 
was previously demonstrated that C-terminal PKA phosphorylation sites were unnecessary for β-
adrenergic regulation of CaV1.2 [159]. To test predicted phosphorylation sites that are upstream 
of the C-terminus, our lab identified and mutated to alanine 18 conserved Ser and Thr residues 
within 28 PKA-consensus phosphorylation sites before the C-terminal region previously deleted 
of human β2B (“18-mutant”). Because there is no method to pharmacologically isolate CaV1.2 
channels bound to transgenic β2, we relied on overexpression of transgenic β2 to outcompete 
endogenous CaVβ subunits [166]. GFP-tagged WT or 18-mutant β2B mice were generated and 
isoproterenol increased peak CaV1.2 current to equal levels in non-transgenic, GFP-WT, and 18-
mutant β2-expressing cells, indicating that direct PKA phosphorylation of sites upstream of the 




Although the 22-mutant α1C cardiomyocytes exhibited unperturbed adrenergic regulation 
of CaV1.2, it remains possible that the functional PKA phosphorylation site is not conserved 
amongst species. Phenotypic differences in eukaryotic species —even those that are closely 
related—are observed in responses to adrenergic stimulation [167]. This can perhaps be 
explained by variation in phosphorylation sites, as gain or loss of phosphorylation sites is 
hypothesized to play a greater role in contributing to phenotypic differences among species than 
the gain or loss of protein kinases [168]. A recent example demonstrated that while parathyroid 
hormone-induced PKA phosphorylation of rabbit TRPV5 enhances channel activity, it did not 
stimulate human TRPV5 activity [169]. By mutating all conserved and non-conserved PKA 
phosphorylation sites between the 5 species mentioned above, we can test the following 
hypotheses that might explain why a consensus phosphorylation site hasn’t been identified: (i) 
that the phosphorylation of any one of several CaVα, CaVβ, or both CaVα and CaVβ residues can 
induce the adrenergic stimulation of CaV1.2 current (redundancy), (ii) that each phosphorylated 
residue contributes a small fraction of the total effect, and/or (iii) that the critical PKA 
phosphorylation sites are not on CaVα or CaVβ.  
 
1.3 Results 
To test the hypotheses outlined above, we started by replaced with Ala all consensus 
intracellular PKA phosphorylation sites in CaV1.2 α1C that are conserved in the rabbit, human, 
guinea pig, mouse, and rat. The optimal PKA phosphorylation motif is a tetrapeptide with Arg at 
the second and third positions (termed -2 and -3) before the phosphorylated Ser or Thr and a 
large hydrophobic residue immediately thereafter (R-R-X-S/T-Φ) [170, 171]. The requirement 
for a positive charge is highest for residues at -2 and -3, but can be found for residues as far as 
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position −6 in PKA target sites [172]. The positions between -4 and -1 have a strong preference 
for Arg and, to a lesser extent, for His or Lys [171, 173]. We identified all potential intracellular 
PKA phosphorylation sites in rabbit α1C using both manual sequence analysis and several web-
based PKA phosphorylation prediction tools, including prediction of protein kinase A 
phosphorylation sites using the simplified kinase binding model (pKaPS) [174], Disorder-
Enhanced Phosphorylation Sites Predictor (DISPHOS) [175], GPS [176], NetPhos [177], and 
Scansite [178]. For identified sites, we also mutated additional Ser and Thr within several amino 
acid residues C-terminal to the Arg or Lys to ensure that we fully tested each phosphoregulatory 
site (Figure 1A).  
 
Our first goal was to determine whether elimination of conserved and non-conserved 
PKA phosphorylation sites in α1C prevented CaV1.2’s responsiveness to β-adrenergic modulation 
in cardiomyocytes. Based on the list of potential PKA phosphorylation sites, we generated 
transgenic mice with inducible cardiomyocyte-specific expression of an N-terminal 3× FLAG-
epitope–tagged DHP-resistant α1C with Ala substitutions of all predicted Ser or Thr conserved 
and non-conserved between 5 species, including residues on the 22-mutant construct previously 
shown to be not required for β-adrenergic stimulation of CaV1.2 (Figure 1B). We mutated all 51 
serine and threonine residues within the 35 intracellular PKA consensus phosphorylation sites of 
rabbit α1C to alanine (“35-mutant”). Several predicted PKA phosphorylation sites in the 
transmembrane and extracellular regions were not mutated, as these are unlikely to have access 
to intracellular PKA. Additionally, two predicted sites that were very close to a transmembrane 
region (Ser607 and Ser680/683) were mutated in isolation and, when expressed heterologously, 




Figure 1. Cardiac-specific, DHP-resistant 35-mutant α1C. (A) Left column, the 35 putative PKA phosphorylation 
sites in rabbit α1C. Center, the 51 residues in red are either predicted phosphorylation sites or within the immediate 
region of the predicted phosphorylation sites. Right, all 51 residues were replaced with alanine in 35-mutant α1C 
transgenic mice. (B) Diagram showing rabbit cardiac α1C. Red dots indicate putative sites of phosphorylation by 
PKA. (C) Diagram showing the binary transgene system that permits robust expression of Flag-tagged DHP-
resistant (DHP*) α1C only in the presence of both rtTA and doxycycline (Tet-ON). The top diagram shows 
expression of the rtTA driven by the cardiac-specific α-myosin heavy chain (α-MHC) promoter. The lower diagram 
shows cDNA for Flag–DHP*–α1C ligated behind seven tandem tetO sequences, which impart tetracycline regulation. 
Figures adapted from [179]. 
 
Previously generated pWT α1C transgenic mice were compared to 35-mutant mice [150]. 
In pWT and 35-mutant cells, the transgenic and endogenous CaV1.2 currents are distinguishable 
by application of nisoldipine, a Ca2+-channel DHP antagonist [150]. Nisoldipine (300 nM) 
inhibited about 70% of peak current in cardiomyocytes isolated from doxycycline-fed pWT α1C 
transgenic mice and about 73% of peak current in doxycycline-fed 35-mutant α1C transgenic 
mice (Figure 2A). This indicates that approximately 30% and 28% of the peak current in the 
cardiomyocytes isolated from pWT α1C and 35-mutant doxycycline-treated transgenic mice, 
respectively, was insensitive to nisoldipine. In the cardiomyocytes isolated from pWT α1C 
transgenic mice, isoproterenol increased the nisoldipine-insensitive peak current by a mean of 
Cardiac-Specific Tet-ON





1.89 ± 0.08-fold (Figure 2B). In the cardiomyocytes isolated from the 35-mutant, isoproterenol 
and forskolin increased nisoldipine-resistant peak CaV1.2 current by a mean of 1.74 ± 0.08-fold, 
which is not significantly different from the isoproterenol-induced augmentation of nisoldipine-
resistant current in pWT α1C transgenic cardiomyocytes (Figure 2B). A hyperpolarizing shift in 
the V50 of activation from both transgenic mutants was observed, characteristic of β-adrenergic 
regulation of CaV1.2 (Figure 5C). These results indicate that phosphorylation of α1C alone is not 
required for β-adrenergic regulation of CaV1.2.  
 
Figure 2. 35-mutant α1C responds to adrenergic regulation. (A) Exemplar whole-cell CaV1.2 currents of 35-
mutant α1C cardiomyocytes (from transgenic mice) in nisoldipine before (black trace) and after (blue trace) treatment 
with isoproterenol. Representative of 25 experiments; pA pf-1, picoamperes per picofarad. (B) Fold change in peak 
DHP-resistant Ca2+ current at 0 mV caused by isoproterenol or forskolin. Data are mean ± s.e.m.; P = 0.39 by 
unpaired two-tailed t-test; n = 45 cardiomyocytes from 5 mice (isoproterenol); n = 25 cardiomyocytes from 5 mice 
(forskolin). Figure adapted from [179]. 
 
The functional PKA phosphorylation site might also be on the CaVβ subunit. Although 
previous data have demonstrated that, separately, the N-terminal and the C-terminal putative 
PKA phosphorylation sites are not required for β-adrenergic regulation of CaV1.2 [159, 165], it 
remains possible that a redundancy exists such that a combination of sites on the N- and C-
terminus confer channel regulation. In the same vein as the 35-mutant α1C, we mutated to alanine 
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all 37 serine and threonine residues within 28 predicted PKA-consensus phosphorylation sites of 
human β2B (“28-mutant”) (Figure 3, A and B). We generated transgenic mice with inducible 
cardiomyocyte-specific expression of either GFP-tagged WT or 28-mutant β2B subunits (Figure 
3C).  
 
Figure 3. Cardiac-specific, 28-mutant β2B. (A) Left, the 28 putative PKA phosphorylation sites in the N-terminal 
(NT), Hook, GK and C-terminal (CT) domains of β2B. Centre, the 37 residues in red are either predicted 
phosphorylation sites or within the immediate vicinity of predicted phosphorylation sites, and were mutated to 
alanine in the 28-mutant GFP-tagged β2B transgenic mice (right). (B) Diagram showing rabbit cardiac α1C (ribbon 
diagram adapted from [180]). Red dots indicate putative sites of phosphorylation by PKA. GK, guanylate kinase 
domain; SH3, Src homology 3 domain; AID, alpha interaction domain; HOOK region. (C) Diagram showing the 
binary transgene system that permits robust expression of GFP-tagged β2B only in the presence of both rtTA and 
doxycycline (Tet-ON). Format as in Figure 1C. Figures adapted from [179]. 
 
The GFP-WT and 28-mutant β2B transgenic mice were fed doxycycline for up to 1 week, 
thus ensuring high levels of expression of the GFP-tagged β2 subunits (Figure 4A). 
Cardiomyocytes expressing green fluorescent protein (GFP)-tagged WT β2B displayed an 
isoproterenol and forskolin-induced stimulation of CaV1.2 current amplitude by 1.48 ± 0.05-fold. 
In the cardiomyocytes isolated from the 28-mutant, isoproterenol and forskolin increased peak 













isoproterenol-induced augmentation of current in GFP-WT β2B transgenic cardiomyocytes 
(Figure 4, B and C). Interestingly, both of these fold-change values are lower than those 
observed in wild-type and even 35-mutant cardiomyocytes. It is likely that overexpression of 
CaVβ increased the number of functional channels in the sarcolemma and decreased the 
magnitude of PKA regulation relative to wild-type cells as previously reported [153, 158]. A 
hyperpolarizing shift in the V50 of activation in both transgenic mutants was observed, similar to 
the isoproterenol-induced shift observed for wild-type mice, pWT α1C, and the 35-mutant (Figure 
5C). 
Figure 4. 28-mutant β2B responds to adrenergic regulation. (A) Fluorescence imaging of isolated cardiomyocytes 
expressing the GFP-tagged 28-β mutant. Representative of images from more than five biologically independent 
mice. (B) Exemplar whole-cell CaV1.2 currents of cardiomyocytes from GFP-tagged 28-mutant β2B transgenic mice 
in nisoldipine before (black trace) and after (blue trace) treatment with isoproterenol. (C) Fold change in peak Ca2+ 
current caused by isoproterenol or forskolin for cardiomyocytes isolated from transgenic mice expressing GFP-
tagged wild-type (WT) β2B subunit [165] and GFP-tagged 28-mutant β2B, or both 35-mutant α1C and GFP-tagged 
28-mutant β2B. Data are mean ± s.e.m.; P = 0.27 by one way-ANOVA; n = 19, 8 and 21 cardiomyocytes from 4, 4 
and 3 mice, from left to right. Figures adapted from [179]. 
 
The data thus far suggest that the functional PKA target for adrenergic regulation is likely 
not solely α1C or solely on β2, based on our observation that eliminating all conserved and non-
conserved consensus PKA phosphorylation sites in α1C and β2 did not alter PKA-mediated 
upregulation of CaV1.2. This means that either there is redundancy between α1C and β subunits, 
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such that PKA phosphorylation of either subunit is sufficient to mediate adrenergic regulation of 
Ca2+ channels in the heart, or that PKA phosphorylation of the core CaV1.2 subunits, α1C and β, 
are not necessary for β-adrenergic regulation of the Ca2+ influx in the heart. To address this, we 
crossed 35-mutant α1C with 28-mutant β2B transgenic mice (“35α x 28β”). 
 
Figure 5. 35α x 28β exhibits unaltered adrenergic regulation. (A) Anti-Flag antibody (upper) and anti-β antibody 
(lower) immunoblots of anti-Flag antibody immunoprecipitations from cleared lysates of hearts from pWT, 35-α and 
three mice expressing 35-α × GFP-tagged-28-β. Representative images from two independent experiments. (B) 
Exemplar whole-cell CaV1.2 currents of cardiomyocytes from 35-mutant α1C crossed with 28-mutant β2B transgenic 
mice. (C) Combined bar and column scatter plot of Boltzmann function parameters, V50. Data are mean ± s.e.m. 
**P < 0.01; ***P < 0.001; ****P < 0.0001 by paired two-tailed t-test. pWT α, n = 19; 35-α mutant, n = 14; 28-β 
mutant, n = 16; 35-α mutant × 28-β mutant, n = 24. (D) Graph showing isoproterenol- and forskolin-induced 
increases in nisoldipine-resistant current, stratified by total basal current density before nisoldipine treatment. 
Figures adapted from [179]. 
 
Immunoprecipitation with anti-Flag antibody indicated that GFP-tagged 28-mutant β2B 
subunits dominate in the 35-mutant α1C complex (Figure 5A) in cardiomyocytes isolated from 
these mice. It has been previously demonstrated that acutely expressed exogenous β-subunits 
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out-compete β subunits present in channels preexisting in the plasma membrane in Xenopus 
oocytes [166]. 35α x 28β cardiomyocytes displayed an isoproterenol- and forskolin-induced 
increase in peak Ca2+ current by 1.45 ± 0.05-fold (Figure 4C and Figure 5B) and a 
hyperpolarizing shift in the V50 of activation (Figure 5C). As seen in pWT α1C, 35-mutant α1C, 
GFP-WT β, and 28-mutant β, the magnitude of the isoproterenol-induced increase in the 
nisoldipine-resistant Ca2+ current in cells from 35α x 28β mice was inversely correlated with the 
basal total CaV1.2 current (Figure 5D). These results indicate that β-adrenergic stimulation of 
CaV1.2 does not involve direct phosphorylation of α1C or β2 subunits, providing the most 
definitive answer about whether PKA phosphorylation of any a1C or β2 residues is necessary. 
 
Given the results above, our lab hypothesized that a CaV1.2 regulator in its 
macromolecular complex plays a role in PKA-mediated upregulation of channel function and 
may be the functional target of PKA phosphorylation. Work performed by other members of the 
Marx laboratory using proximity labeling and mass spectrometry observed the movement of Ca2+ 
channel inhibitor Rad away from CaV1.2 in cardiomyocytes after application of isoproterenol 
[179]. Heterologous expression of wild-type α1C, β2B, and Rad enabled reconstitution of 
forskolin-induced stimulation of CaV1.2 in HEK cells. As confirmation of my studies, we 
expressed in HEK293 cells 35-mutant α1C and 28-mutant β2B with and without Rad. Forskolin 
did not increase the maximal current density of CaV1.2 channels comprised of 35-mutant α1C 
with 28-mutant β2B (0.97 ± 0.04-fold change), but forskolin increased peak current density by 
1.91 ± 0.12-fold when co-expressing 35-mutant α1C, 28-mutant β2B, and Rad (Figure 6, A and B). 
A forskolin-induced hyperpolarizing shift in the V50 of activation was observed for 35-mutant 
α1C, 28-mutant β2B, and Rad, but not in cells without Rad coexpression (Figure 6C). This implies 
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that similar to cardiomyocytes, phosphorylation of α1C and β2B subunits is not required for β-
adrenergic upregulation of heterologously expressed CaV1.2 channels. 
 
Figure 6. Rad is required for forskolin-induced activation of heterologously expressed CaV1.2 channels. (A) 
Upper, a 200-ms voltage ramp from −60 mV to +60 mV was applied every 10 s. Lower, Exemplar traces of Ba2+ 
currents in the absence and presence of Rad elicited by voltage ramp every 10 s. Black traces, before forskolin 
treatment; blue traces after treatment; no Rad, 7 cells; Rad, 16 cells. (B) Fold change in Gmax induced by forskolin in 
the absence and presence of Rad. Data are mean ± s.e.m.; ****P < 0.0001 by unpaired two-tailed t-test. n = 7 and 
16, from left to right. (C) Boltzmann function parameter V50. Data are mean ± s.e.m. **P < 0.01 by paired two-
tailed t-test. n = 7 and 16, from left to right. Figures adapted from [179]. 
 
1.4 Discussion 
Previously, our lab showed that in cardiomyocytes expressing α1C with mutations at 
consensus PKA phosphorylation sites that are conserved between 5 species, β-adrenergic 
regulation of CaV1.2 was preserved [164]. Since our lab only investigated conserved residues, it 
could not be ruled out that predicted PKA phosphorylation sites that are not conserved amongst 
the 5 species contribute to adrenergic regulation of CaV1.2. Different eukaryotic species exhibit 
phenotypic differences in β-adrenergic regulation of the heart [181, 182], and variation of 
phosphorylation sites has been suggested as an explanation for these distinctions [168, 183]. 
Additionally, we previously showed that cardiomyocytes from transgenic mice expressing β2 
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with mutated PKA sites upstream from the C-terminus did not show altered β-adrenergic 
regulation of CaV1.2 either [165]. These results foster several hypotheses. It was possible that 
redundancy existed between α1C and β2 so that phosphorylation of either subunit could cause in 
increase in Ca2+ current. If true, we would not observe alterations in regulation with coexpression 
of one a mutated subunit alongside endogenous expression of the other subunit. Expanding on 
this idea, redundancy might additionally exist between a conserved and non-conserved site the 
α1C subunit, or between a C-terminal and N-terminal site the β2 subunit. Finally, phosphorylation 
of several sites on α1C, β2, or both might each confer an incremental increase that amounts to the 
observed regulation. By mutating all conserved and non-conserved predicted PKA 
phosphorylation sites on both α1C and β2 and expressing the mutated subunits together, we were 
able to test these hypotheses. Adrenergic regulation was unperturbed in our experiments with 
these mutants in cardiomyocytes and in heterologous expression systems with Rad, providing the 
definitive answer that PKA phosphorylation of any α1C and β2 residues is not necessary for 
adrenergic stimulation of cardiac Ca2+ current.  
 
Although heterologous expression of CaV1.2 channels has proven useful for investigating 
biophysical properties, it has not been as successful for exploring physiological modulation in a 
cardiomyocyte milieu. Our approach of expressing doxycycline-inducible, tissue-specific CaV1.2 
subunits allowed us to study adrenergic regulation robustly in the native cardiomyocyte. There 
are drawbacks, however, to using our approach. Though acute, overexpression of α1C or β2 
transgenes can reduce the hormonal regulation of the channel [158, 184]. Stratifying the 
magnitude of β-adrenergic-mediated upregulation of CaV1.2 current by total basal current density 
exemplifies this phenomenon (Figure 5D). Notably, GFP-WT β, 28-mutant β, and 35α x 28β all 
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had a relatively smaller fold-change after β-adrenergic stimulation compared to pWT α1C and 35-
mutant α1C. This is likely due to an increased the number of functional channels in the 
sarcolemma as overexpression of the β2b subunit in cardiomyocytes increases the maximum 
gating charge (Qmax; representing number of voltage-gated channels expressed in the membrane) 
and reduces response to β-adrenergic stimulation [153, 158]. This saturable modulation where an 
inverse hyperbolic relationship is observed between basal current and fold-change in current 
after β-adrenergic activation suggests a limiting resource for PKA modulation of CaV1.2. Recent 
results call Rad into question as the limiting factor in this process. If so, this would mean that as 
more channels are expressed, fewer are inhibited under basal conditions and capacity for 
upregulation is muted. 
 
Another potential confounding variable in our results is the presence of non-transgenic 
current remaining after 300nM nisoldipine is applied to cardiomyocytes isolated from 35-mutant 
and 35α x 28β transgenic mice. The 35-mutant α1C subunit was engineered to be relatively DHP-
insensitive with the substitutions T1066Y and Q1070M [138, 139]. The IC50 for nisoldipine 
block of heterologously expressed WT α1C was 12 nM, whereas the IC50 for pWT α1C was 650 
nM. A nisoldipine concentration of 300nM was the optimal concentration for inhibiting >98% of 
heterologously expressed WT α1C and only 34.6% of heterologously expressed DHP-insensitive 
α1C. In cardiomyocytes, 300nM nisoldipine blocked about 93% of current from non-transgenic 
mice, and about 70% of current from pWT α1C mice. From these measurements, we can assume 
that about 7% of endogenous current is not blocked by nisoldipine and 65% of DHP-insensitive 
transgenic channels are not blocked by nisoldipine. Nisoldipine blocked about 73% of current in 
cardiomyocytes isolated from 35-mutant mice and about 58% of current in cardiomyocytes 
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isolated from 35α x 28β. The maximal contamination of nisoldipine-resistant currents by 
endogenous channels, determined by first calculating the fraction of endogenous current of total 
current, would be ~17% in 35-mutant cells and ~7% in the 35α x 28β cells [150]. These 
percentages are relatively small and would not materially impact our interpretations that the 
transgenic channels are regulated by adrenergic stimulation.  
 
Previous results demonstrating phosphorylation of CaV1.2 at Ser1928, Ser1700, or other 
sites raises fundamental questions about the functional role of PKA phosphorylation of CaV1.2. 
CaV1.2 is the most abundant L-type Ca2+ channel isoform in the mammalian heart, brain, and 
vascular smooth muscle [185]. Its dysfunction leads to a range of disorders in these tissues, for 
example cardiac arrhythmias, autistic-like behavior, and developmental abnormalities in 
Timothy syndrome patients [22]. Due to this relative ubiquity, it would make sense that tissue-
specific nuances exist to precisely tune CaV1.2 function. In hippocampal neurons, the β2-
adrenergic receptor binds directly to the C‐terminus of CaV1.2, resulting in in localized cAMP 
signaling [186, 187]. Phosphorylation of Ser1928 in hippocampal neurons displaces the β2-
adrenergic receptor from CaV1.2 [188]. Single-channel recordings with isoproterenol in the 
pipette showed an increase in NPO but, when cells were preincubated with isoproterenol, 
upregulation of channel activity was not observed unless the washout was 10 minutes long, 
indicating that displacement of the β2-adrenergic receptor is a negative feedback regulatory 
mechanism for limiting Ca2+ influx that is unseen in cardiomyocytes. Of note, Ca2+ channel 
activator BayK8644 was used in the patch pipette solution, and it remains to be shown if results 
are dependent on the presence of BayK8644. Also, unlike cardiomyocytes, β1-adrenergic 
receptor stimulation does not cause increase CaV1.2 activity in neuronal cultures [189]. In 
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smooth muscle cells, stimulation of β-adrenergic receptors leads to membrane hyperpolarization, 
indicating that K+ channels are activated [190, 191]. Seemingly paradoxical results have shown 
that PKA-dependent phosphorylation of Ser1928 enhances vascular CaV1.2 activity, although 
this regulation is most apparent in conditions of high blood glucose [192]. AKAP50 is required 
for this regulation, leading to the hypothesis that compartmentalization of a subpopulation of 
CaV1.2 channels are responsible for activating K+ channels. Supporting this, previous reports 
have demonstrated the association of Ca2+ channels and Ca2+-activated BK channels in complex 
[193, 194].  
 
1.5 Conclusion 
PKA-mediated adrenergic regulation of CaV1.2 channels in the heart is key to normal 
cardiac physiology [30]. Using mutagenesis to eliminate all potential PKA phosphorylation 
targets on α1C and β2, we show that phosphorylation of these CaV1.2 subunits is not required for 
β-adrenergic upregulation of the channel in cardiomyocytes. Additionally, we reconstituted β-
adrenergic regulation of CaV1.2 in heterologous expression systems using the cDNA of mutated 
α1C and β2 plus Rad. The identification of this mechanism could offer opportunities to develop 
specific modulators of the sympathetic nervous system modulation of Ca2+ currents for patients 
with heart failure for instance. Future projects will also explore the role of Rad phosphorylation 
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Incomplete inactivation of NaV1.5 leads to persistent inward late Na+ influx (INa,L). Even 
though INa,L is diminutive compared with the peak Na+ current, increased INa,L counteracts 
repolarization and is sufficient to trigger LQT3 and cause structural and electrical remodeling in 
the atria of mice [195, 196]. Interaction of the NaV1.5 III-IV linker and the C-terminus stabilizes 
fast inactivation and disruption of this interaction was found to increases INa,L, indicating a role 
for the C-terminus in modulating INa,L [53]. The C-terminus of NaV1.5 consists of several protein 
interaction domains and is a hotspot for mutations linked to LQT3, suggesting that these domains 
may be required for tuning physiologic INa,L [197].  
 
Calmodulin (CaM) is a Ca2+ sensing protein that interacts with the “IQ” domain within 
the C-terminus of NaV1.5 via its C-lobe [198]. The IQ domain of nearly all NaV channels binds to 
both Ca2+-free CaM (apoCaM) and Ca2+/CaM [199, 200]. Considerable efforts have been devoted to 
identifying the Ca2+ dependent effect on NaV1.5 gating. Although some studies have shown that 
Ca2+ elevation elicits a depolarizing shift in channel steady-state inactivation, recent studies using 
rapid Ca2+ delivery techniques have suggested otherwise [54, 71]. Besides the Ca2+-dependent 
effects, the loss of apoCaM binding to the NaV1.5 by mutations of the IQ domain has been shown to 
increase INa,L in heterologous expression systems [73], suggesting an impact of apoCaM in stabilizing 
the interaction between III-IV linker and the C-terminus [75]. Additionally, human mutations within 
the IQ motif or in close vicinity within the CaM binding pocket — including Q1909R, E1901Q, 
and R1913H — are associated with LQT3 and cause increased late Na+ current when expressed 
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in heterologous cells [72]. Although these results are highly indicate loss of apoCaM increases 
INa,L, this has not been tested in native cardiomyocytes. NaV1.5 function is exquisitely tuned by a 
rich repertoire of modulatory proteins that may be present in cardiomyocytes but not in 
heterologous expression systems, including fibroblast homologous growth factor (FHF) FGF13. 
 
2.2 Experimental Design and Approach 
Many of the prior studies on CaM and FGF13 regulation of INa,L have been carried out in 
heterologous expression systems that might not properly represent the proteomic profile of 
cardiomyocytes. To study the effects of CaM binding in cardiomyocytes, we created transgenic 
mice with tetO–3XFLAG epitope–tagged, TTX-sensitive (C374Y) NaV1.5 channels (designated 
pseudo-WT, pWT). The channel was engineered to be TTX sensitive with the substitution of 
C374Y [201], as NaV1.5 channels are relatively resistant to TTX compared with neuronal and 
skeletal muscle isoforms. In the pWT background, we created additional transgenic mice 
expressing Ala substitutions for IQ motif (IQ/AA), which prevents CaM binding to the C-
terminus of NaV1.5. TTX-sensitivity was used to distinguish transgenic from endogenous Na+ 
channels rather than lidocaine resistance (F1759A) as it had previously shown that this mutation 
results in significantly increased INa,L [196]. Instead, we used a previously-made tetO-F1759A 
mutant mouse as a positive control for increased INa,L relative to the pWT mouse. The tetO-
NaV1.5 mice were crossed to transgenic mice expressing rtTA controlled by the cardiac-specific 
α-MHC promoter (Figure 1A). The bitransgenic tetracycline-regulated system enables robust 
expression of the FLAG-tagged transgenic NaV1.5 channels only when both transgenes and 
doxycycline were present. Since the expression of these channels is inducible and cardiac 
specific, there is a low likelihood of developmental or other compensatory mechanisms affecting 
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the phenotype. We use both whole-cell and cell-attached approaches in isolated cardiomyocytes 
from pWT and IQ/AA mice to explore of the effect of NaV1.5 regulatory proteins on INa,L.  
 
2.3 Results 
The sum of the endogenous Na+ currents and the transgenic NaV1.5 current make up the 
total peak Na+ current in the transgenic cardiomyocytes. Application of 20 nM TTX had no 
effect on peak endogenous Na+ currents in cardiomyocytes isolated from nontransgenic animals 
due to the relative resistance of endogenous cardiac NaV1.5 to TTX (Figure 1, B and E). In 
cardiomyocytes isolated from pWT or IQ/AA transgenic mice, in contrast, 20 nM TTX reduced 
the peak Na+ current, implying that the transgenic channels were expressed, inserted in the 
membrane, and were functional (Figure 1, C-E). The difference between the total current and the 
remaining current after TTX infusion represents the current carried by the transgenic pWT or 
IQ/AA channels. The mean fraction of TTX-sensitive current, which can be attributed to the 





Figure 1. Cardiac-specific, FLAG-tagged TTX-sensitive NaV1.5-expressing transgenic mice. (A) Schematic of 
binary transgene system. The expression of reverse tetracycline-controlled transactivator (rtTA) is driven by the 
cardiac-specific α-myosin heavy chain promoter. The cDNAs for FLAG-F1759A-NaV1.5 or FLAG-tagged TTX-
sensitive NaV1.5 were ligated behind 7 tandem tetO sequences. (B–D) Exemplar whole cell Na+ current trace of 
ventricular cardiomyocyte from nontransgenic, pWT, and IQ/AA transgenic mice in the absence (black) and 
presence (red) of 20 nM TTX. Representative of n = 13, 21, and 44 cells, from left to right. Vertical scale bars: 10 
pA/pF; horizontal scale bars: 5 ms. (E) Graph showing effect of 20 nM TTX on peak Na+ current. ****P < 0.0001 
by paired t test. For nontransgenic, P = 0.61. n = 13, 21, and 44 cells from left to right. (F) Graph of fraction 
transgenic Na+ current for pWT and IQ/AA. Mean ± SEM. n = 21 and 44 cells from left to right. P = 0.73 by t test. 
 
For whole-cell analysis, we normalized INa,L to the peak Na+ current in order to account 
for changes in peak Na+ current that may occur due to variability in channel expression in a 
transgenic model [196]. To proceed this way, determination of extracellular Na+ concentration 
when taking measurements of peak Na+ current and INa,L must be carefully considered due to the 
low magnitude of INa,L in relation to the peak (<1%). Nonselective membrane leak or digitization 
artifacts could corrupt accurate resolution of small-amplitude INa,L if the driving force is too 
small. On the other hand, when INa,L is amplified by large ionic gradients, the amplitude of the 
peak INa becomes large and vulnerable to voltage-clamp artifacts. To overcome these limitations, 
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we devised a protocol whereby the INa,L is measured using 100 mM Na+ and the peak Na+ current 
is measured using 3 mM or 5 mM Na+ in the extracellular solution. INa,L was quantified as the 
difference in currents during the final 10 ms of a 190-ms depolarization with 100 mM Na+ in the 
extracellular solution, before and after application of either TTX or ranolazine, a selective 
blocker of INa,L (Figure 2, A-D). After wash-out of ranolazine or TTX, peak current was 
measured with 3 mM Na+ in the extracellular solution in the absence and presence of 20 nM 
TTX for pWT or IQ/AA transgenic mice or 3 mM lidocaine for F1759A transgenic mice. 
Normalization of INa,L to the peak Na+ current yielded a late-current ratio enabling comparison 
between transgenic models. All recordings were performed with BAPTA in the patch pipette to 
chelate intracellular Ca2+, thus querying the role of apoCaM. 
 
The late-current ratio was not different between nontransgenic and pWT cardiomyocytes, 
implying that overexpression of TTX-sensitive pWT in these cells does not increase INa,L relative 
to nontransgenic cells (Figure 2E). Similarly, the late-current ratio was not increased in the 
IQ/AA mice compared with either the late-current ratio in nontransgenic or pWT mice (Figure 
2E). This finding was different than previously reported results in a heterologous expression 
system showing disruption of CaM interaction causes increased INa,L [72, 73]. Conversely, the 
late-current ratio from mutant F1759A cardiomyocytes was markedly increased compared with 
nontransgenic, pWT, and IQ/AA mice (Figure 2, D-E). This is consistent with previous reports 





Figure 2. Whole-cell analysis demonstrated late Na+ current is not increased in cardiomyocytes expressing 
IQ/AA NaV1.5. (A–D) Exemplar whole cell Na+ current traces of ventricular cardiomyocytes isolated from 
nontransgenic, pWT, IQ/AA, and F1759A mice. Experiments designed to assess late Na+ current using a 190 ms 
depolarization from a holding potential of –110 to –30 mV in the absence and presence of 500 μM ranolazine or 40 
μM TTX; intracellular solution contained 5 mM Na+ and extracellular solution contained 100 mM Na+. Horizontal 
scale bars: 50 ms; vertical scale bars: 10 pA/pF. (E) Graph of fraction of late Na+ current normalized to peak 
Na+ current. Mean ± SEM, ****P < 0.0001 by Kruskal-Wallis test with Dunn’s multiple comparison test. n = 23, 
25, 29, and 31 cardiomyocytes from left to right. 
 
To further dissect INa,L in the pWT, IQ/AA, and F1759A transgenic models, we 
undertook cell-attached multichannel recordings to directly measure late-channel openings [67, 
203]. A 300 ms depolarizing pulse from a holding potential of -120 to -30 elicits channel 
openings, as evident in a patch from pWT transgenic mice (Figure 3A). Rapid activation 
followed by inactivation of multiple channels within the patch result in stacked channel openings 
reflecting near-macroscopic peak current. Late openings can be observed following 50ms of 
depolarization and occur to the unitary current level, allowing the distinction from instrument 
noise and baseline level. For channels from pWT myocytes, we observed sparse late-channel 
openings, consistent with near-complete inactivation (Figure 3A, shaded area and inset). For 
each patch, we obtained 50–100 stochastic traces to compute an ensemble average current, which 
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is equal to the unitary current level (i) x the number of channels in the patch (N) x open 
probability (PO). The ensemble average current was subsequently divided by the unitary current 
level (i) to obtain late NPO. Peak NPO is calculated from the ensemble average peak current. To 
assess late openings, we normalize late NPO trace by peak NPO to obtain a normalized time-
dependent late PO waveform for each patch (Figure 3B) and compute the mean value following 
50 ms of depolarization (Figure 3G). Like pWT, multichannel recordings from IQ/AA transgenic 
cardiomyoyctes also showed minimal late-channel openings, as evident from exemplar trace 
(Figure 3C) and ensemble average (Figure 3D). By comparison, Na+ channels from F1759A 
cardiomyocytes showed incomplete inactivation with frequent channel openings 50 ms following 
depolarization (Figure 3, E and F). The ratio of late-to-peak open probability was significantly 
increased for F1759A channels but not for IQ/AA channels compared with the control channels 
(Figure 3G).  
 
 
Figure 3. Multichannel macropatch analysis demonstrates late Na+ current is not increased in cardiomyocytes 
expressing IQ/AA NaV1.5.  (A) Multichannel record from pseudo-WT myocyte shows rapid Na+ channel activation 
and inactivation, followed by a rare opening in the late phase, following 50 ms of depolarization (gray shaded 
region). Inset shows lone NaV1.5 opening to unitary current level (dashed line) in the late phase. Vertical scale bar: 
10 pA; horizontal scale bar: 100 ms. (B) Normalized ensemble-average open probability relation computed from 
50–80 stochastic records. Inset shows low levels of late PO following 50 ms of depolarization. Vertical scale bar: 
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25% for normalized PO (PO(t)/PO,peak). PO(t), time-dependent open probability; PO,peak denotes the peak open 
probability. (C and D) Multichannel recordings of Na+ channels from IQ/AA mice show minimal late current similar 
to pWT myocytes. Format as in A and B. (E and F) Appreciable late Na+–channel openings were detected for 
F1759A mutant. Format as in A and B. (G) Graph of PO normalized to peak PO. Mean ± SEM, **P < 0.001 by 
Kruskal-Wallis test, **P < 0.01 by Dunn’s multiple comparison test. Multichannel macropatch analysis performed 
with the assistance of Nourdine Chakouri and Manu Ben-Johny. 
 
In assessing possible mechanisms that might mask increased INa,L in our transgenic 
models, we considered contributions of INa,L from other Na+ channel isoforms. NaV1.8 (Scn10a) 
has been reported to play a role in promoting arrythmias, and immunohistochemistry methods 
have been used to show NaV1.6 (Scn8a) expression in the heart [204, 205]. To test what Na+ 
channel isoforms are present and are affected by transgene expression, we measured the 
transcript levels of endogenous mouse Scn5a, Scn8a and Scn10a and transgenic human SCN5A 
in mouse heart samples via rt-PCR. In pWT, IQ/AA, and F1759A mice, human SCN5A is 
substantially expressed (data not shown). Scn8a and Scn10a, on the other hand, did not reach the 
significant threshold value after 40 cycles in all mouse hearts, indicating negligible amount of 
expression. 
 
Our results indicate the existence of INa,L protective mechanisms present in the 
cardiomyocyte that are not in heterologous expression systems. We reasoned that a modulator 
uthat interacts with NaV1.5 may play a protective role in prevention of increased INa,L. FHF 
proteins have been shown to modify multiple aspects of NaV channel inactivation and INa,L is 
increased in heterologously expressed NaV1.5 channels with mutations at one of the 
hypothesized binding sites for FGF13 [74]. In heterologous expression systems, co-expression of 
FGF13 with NaV1.5 reduced INa,L compared to expression of NaV1.5 alone [206]. We reasoned 




We hypothesized that co-expression of FGF13 with mutant IQ/AA in HEK293 cells 
rescues the increased INa,L phenotype previously observed in heterologous expression systems 
[72, 73]. As a control, we quantified late-channel openings from WT NaV1.5 channels in the 
presence and absence of FGF13 using multichannel cell-attached recordings. At baseline, WT 
channels exhibited minimal late-channel openings (Figure 4, A and B), and FGF13 coexpression 
had no appreciable effect (Figure 4, C, D, I, and J). Per contra, expression of NaV1.5 IQ/AA 
mutant alone revealed late-channel openings (Figure 4, E and F) with an 11-fold increase in INa,L 
(Figure 4, I and J), consistent with previous studies. To mimic the colocalization of FHF with 
NaV1.5 in cardiomyocytes, we coexpressed FGF13 with NaV1.5 IQ/AA mutant. This maneuver 
resulted in a complete reversal of INa,L to WT levels (Figure 4, G-J), suggesting that the addition 
of FGF13 eliminated INa,L when the IQ motif was completely ablated and reminiscent of the 
absence of INa,L in IQ/AA transgenic cardiomyocytes in which FGF13 is present. These findings 
suggest that endogenous FGF13 in cardiomyocytes may serve a protective function by 





Figure 4. Expression of FGF13 reduces late Na+ current in IQ/AA NaV1.5. (A and B) Multichannel recordings 
show minimal late Na+–channel openings for WT-NaV1.5 expressed in HEK293 cells. Format as in Figure 2, F and 
G. Horizontal scale bar: 100 ms; vertical scale bar: 10 pA (A) and 25% for normalized PO (PO(t)/PO,peak) (B). 
(C and D) Late current of WT-NaV1.5 is unaffected by FGF13 overexpression. Same format as in A and B. 
(E and F) IQ/AA NaV1.5 mutant channel showing enhanced late-channel openings compared with WT-NaV1.5 in 
HEK293 cells. Same format as in A and B. (G and H) FGF13 coexpression with IQ/AA NaV1.5 reverses the 
increase in late current to WT levels. Same format as in A and B. (I) Dot plot summary of PO,late for WT-NaV1.5 and 
IQ/AA NaV1.5 in the presence and absence of FGF13. Mean ± SEM, ***P < 0.0001 by Kruskal-Wallis test with 
Dunn’s multiple comparison test. (J) Graph shows fold-change in PO,late for WT-NaV1.5 and IQ/AA NaV1.5 by 
FGF13. Mean ± SEM, computed from aggregate data in I. Multichannel macropatch analysis performed with the 
assistance of Nourdine Chakouri and Manu Ben-Johny. 
 
In cardiomyocytes, F1759A mutants exhibit a substantial INa,L that causes cardiac 
arrhythmias in mice [196], raising the possibility that these channels are less sensitive to 
endogenous protective mechanisms. To test this possibility, we expressed the NaV1.5 F1759A 
channels in HEK293 cells and undertook multichannel recordings. Similar to cardiomyocytes, 
recombinantly expressed F1759A mutant display markedly increased late openings (Figure 5, A 
and B), as previously reported [202]. Interestingly, the amount of INa,L for F1759A is similar to 
the IQ/AA mutant in the absence of FHFs. In contrast to IQ/AA mutant, however, FGF13 
overexpression exerted negligible effect on the INa,L of F1759A mutation (Figure 5, C-F), thus 
confirming the reduced sensitivity of these channels for FGF13. In all, the differential 
modulation of IQ/AA versus F1759A mutant by FGF13 further elucidates role of FGF13 in 





Figure 5. Late Na+ current for F1759A-NaV1.5 is minimally perturbed by FGF13. (A and B) Multichannel 
recordings show high late Na+ current for F1759A-NaV1.5 mutant when expressed in HEK293 cells. Format as in 
Figure 3, A and B. Horizontal scale bar: 100 ms; vertical scale bar: 10 pA (A) and 25% for 
normalized PO (PO(t)/PO,peak) (B). (C and D) FGF13 coexpression with F1759A-NaV1.5 mutant. Horizontal scale 
bar: 100 ms; vertical scale bar:10 pA (C) and 25% for normalized PO (PO(t)/PO,peak) (D). (E and F) Population data 
confirm minimal change in late PO for F1759A-NaV1.5 with FGF13. Format as in Figure 7 I and J. Open probability 
of late Na+ current from heterologously expressed IQ/AA NaV1.5 (without FHF13) is shown by the dashed blue line. 
Multichannel macropatch analysis performed with the assistance of Nourdine Chakouri and Manu Ben-Johny. 
 
2.4 Discussion 
Increased INa,L originates from failure of NaV1.5 inactivation or the slowing of 
inactivation. Although INa,L amounts to as little as 1% of the INa peak magnitude, increased INa,L 
has been demonstrated in several mutant channels that associate with LQT3 [207]. Aberrant INa,L 
counteracts repolarization and results in heterogenous action potential prolongation that may 
trigger atrial or ventricular arrhythmias [196, 208]. Sustained Na+ influx also causes structural 
abnormalities such as those linked to dilated cardiomyopathy [209]. In heterologous expression 
systems, CaM was shown to regulate of INa,L after mutations on the IQ motif demonstrated 
altered inactivation properties [72, 73]. This finding and multiple subsequent studies of 
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recombinant channels in heterologous expression systems has led to the current dogma that CaM 
is a powerful regulator of cardiac channels. We sought to test this result in in the native 
cardiomyocytes. To do this, we utilized an inducible platform for acutely expressing mutant 
NaV1.5, minimizing previously reported electrophysiological abnormalities to investigate the 
primary effects of altered CaM binding. To this point, acute overexpression of transgenes did not 
alter ventricular repolarization, assessed by both QT interval assessment and optical voltage 
mapping, in pwt or IQ/AA cardiomyocytes relative to non-transgenic cells (data not shown) 
[208]. Furthermore, Na+ current conveyed by the transgenic channels was isolated by 
pharmacological approaches, allowing us to specifically distinguish functional alterations of 
mutant channels from endogenous wild-type channels in the same cells. 
 
To our surprise, we found that IQ/AA mutant did not increase INa,L in cardiomyocytes. 
Both whole-cell analysis of INa,L normalized to peak Na+ current and multichannel macropatch 
analysis of late PO normalized to peak PO showed that each of these ratios from measurements in 
IQ/AA cardiomyocytes were not significantly different than those in pWT cardiomyocytes. 
These findings suggest the existence of endogenous protective mechanisms that counteract the 
increase in INa,L that occurs with loss of CaM binding. We reasoned that additional NaV1.5 
interactors present in cardiomyocytes but perhaps not in HEK cells might play a role in tuning 
INa,L. FGF13 has been previously implicated in the regulation of INa,L [74, 75]. Upon further 
investigation, FGF13 overexpression in HEK293 cells fully reversed the INa,L phenotype of 




CaM regulation of Na+ channels is complex, with differing effects dependent on the 
expression system used, the channel isoform, and the presence of Ca2+. For NaV1.5, mutations in 
the IQ region on the C-terminus has been shown to diminish CaM interaction with NaV1.5 [210]. 
Although the IQ domain of NaV1.5  binds to both Ca2+-free CaM and Ca2+/CaM, [199, 200], 
prior analysis of endogenous NaV1.5  in guinea pig ventricular myocytes revealed no Ca2+-
dependent effects [71]. NaV1.4, by comparison, exhibits a reduction in peak current after 
transient elevation of intracellular Ca2+ concentration. We performed whole-cell experiments 
with BAPTA in the pipette solution, thus querying the role of apoCaM binding to NaV1.5. 
Although BAPTA was not used in our multichannel recordings, we demonstrated the same 
findings of minimally perturbed INa,L in IQ/AA cardiomyocytes. Our results demonstrate the 
differences in channel regulation between NaV1.5 channels expressed in heterologous expression 
systems and cardiomyocytes. While loss of apoCaM preassociation to the NaV1.5 IQ motif 
results in a marked elevation of INa,L in heterologous systems, this effect is not observed in native 
cardiomyocytes. 
 
The absence of an altered phenotype in cardiomyocytes and the rescue of the relatively 
increased INa,L in HEK cells by FGF13 suggest that FGF13 plays a protective, and perhaps 
redundant, role in cardiomyocytes. FGF13 knockdown in mice leads to reduced Na+ current 
density and decreased channel availability with a left shift in channel steady state inactivation 
[211]. Not unlike regulation of NaV1.5 by CaM, inconsistent reports of INa,L modulation by 
FGF13 have also been reported. Yang et al. showed that FGF13 had no effect on INa,L in tsA201 
cells and regulated steady state properties in an isoform-specific manner [212]. Only a year later 
did Burel et al. show that FGF13 decreased INa,L in HEK293 cells, consistent with our 
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multichannel macropatch results in the same cell line [206]. Furthermore, these results were 
abrogated with NaV1.5 mutants mimicking CAMKII phosphorylation, indicating that FGF13 
interaction with the C-terminal tail is influenced by post-transitional modification. These results 
exemplify the variability in results from different cell types, even among heterologous 
expression systems. Consistent with the effect observed in HEK cells, conditional knockout of 
FGF13 in mouse hearts led to a prolonged action potential duration [213]. Future studies that 
knock out FGF13 in the IQ/AA transgenic model will help ascertain the precise contribution of 
FGF13 in attenuating the INa,L in the setting of reduced CaM binding. 
 
Based upon our results, we conclude that CaM and FGF play a redundant role in the heart 
to prevent arrhythmogenic increases in INa,L. This fails to explain, though, why human mutations 
in the IQ region such as Q1909R lead to LQT3 and arrhythmias [214]. One explanation is that 
FGF12, the predominant isoform in the human heart, does not prevent the increase in INa,L in 
humans as FGF13 does in mice. FGF13 binds to the C-terminus of murine NaV1.5 with an 
isothermal calorimetry–determined (ITC-determined) affinity of 16.6 nM, which is 
approximately 10-fold higher than the affinity of FGF12B which is the FHF isoform expressed in 
human cardiomyocytes [199]. Studies of inducible pluripotent stem cell–derived differentiated 
cardiomyocytes may further delineate the role of FGF12 in tuning CaM-deficient NaV1.5 
channels in humans. It also remains possible that post-translational modifications such as those 
described by Burel et al. reduce the interaction of FGF12 and NaV1.5, unveiling the requirement 
for INa,L tuning by CaM. Several cellular conditions have been shown to upregulate INa,L 
including heart failure [215] and hypoxia [216], corroborating possibility that the phenotype of 
Q1909R manifests in specific circumstances. Finally, altered C-terminal interaction with other 
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protein regulators have been shown to influence INa,L [76-78]. Future studies conducted in 
cardiomyocytes will delineate the involvement of endogenous factors.  
 
2.5 Conclusion 
The effect of IQ/AA mutation to increase INa,L in heterologous expression systems has 
been established in the field for over 15 years. This finding and multiple subsequent studies of 
recombinant channels in cell lines has led to the dogma that CaM is a powerful regulator of 
cardiac channels. Here we have explored the effects of disrupting CaM binding to NaV1.5 in 
cardiomyocytes. Our finding that IQ/AA mutant showed no apparent change in INa,L in cardiac 
myocytes exemplifies the importance of performing experiments in native cells. Finally, we 
found that FGF13 diminished INa,L of the IQ/AA, suggesting that endogenous FHFs may serve to 
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SCN5A-encoded NaV1.5 channels drive the rapid inward depolarizing current that 
initiates the cardiac action potential, thereby affecting proper cardiac impulse propagation and 
conduction through the myocardium [217]. Abnormalities in Na+ channel function cause a broad 
spectrum of cardiac arrhythmias, such as LQT3, Brugada syndrome, atrial fibrillation, and heart 
failure [196, 209]. Some of these NaV1.5-related clinical phenotypes are not solely accounted for 
by mutations in NaV1.5. Normal physiologic function of NaV1.5 has been shown to depend on 
the interaction of the channel with several proteins [84] and mutations in the genes that code for 
these regulating proteins have pathological consequences [218, 219]. These regulators exert an 
effect on NaV1.5 in different ways, with some acting as adaptor proteins to traffic and anchor 
NaV1.5 to the sarcolemma, some playing an enzymatic role in post-translationally modifying the 
channel, and some directly binding to and modulating the biophysical properties of NaV1.5. 
Although several studies have provided details on the regulation of NaV1.5 by other proteins, 
insights into how NaV1.5 function is altered in disease through access to modulators of the 
NaV1.5 macromolecular complex remain incomplete. 
 
In this chapter, we apply proximity labeling and multiplexed quantitative proteomics 
approaches to define the NaV1.5 macromolecular complex in healthy murine hearts and identify 
alterations in the early stages of Duchenne muscular dystrophy (DMD), in which the absence of 
dystrophin predisposes affected individuals to arrhythmias and cardiac dysfunction [121]. 
Although DMD is characterized by a relentless decline in skeletal muscle function, the major 
causes of death for individuals affected by DMD are arrhythmias and cardiac failure [220]. 
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Dystrophin serves both as a protein cytolinker within the sarcolemma membrane dystrophin 
glycoprotein complex (DGC), which mediates mechanoprotective crosstalk between the 
cardiomyocyte cytoskeleton and the extracellular matrix [221]. The absence of dystrophin results 
in the dispersion of the DGC protein complex [222], altered ion channel function [223-225], a 
disorganized microtubule cytoskeleton [129, 130], and increased oxidative stress [126, 134], 
which in the DMD heart can initiate congestive heart failure and arrhythmias. 
 
NaV1.5 expression in the cardiomyocytes is hypothesized to segregate into different 
subcellular “pools” where they interact with location-specific proteins. Two pools have been 
described: one at the intercalated disc and one at the lateral membrane and t-tubules [106]. At the 
intercalated disc, NaV1.5 interacts with connexin-43 [226], plakophilin-2 [96], and ankyrin-G [96] 
among other proteins, whereas NaV1.5 at the lateral membrane associates with the DGC [85]. 
Interaction of the NaV1.5 C-terminal PDZ domain-binding motif (SIV motif) with DGC members 
syntrophin and dystrophin (via syntrophin) was established by Gavillet et al [103]. They showed 
that, in the dystrophin-deficient Dmdmdx mouse model, there was a significant ~50% reduction in 
NaV1.5 expression and a corresponding ~30% decrease in whole-cell Na+ current density. The 
conclusion was made that expression and function of NaV1.5 at the lateral membrane is dependent 
upon its association with dystrophin and syntrophin. When expressed in HEK293 cells, mutations 
in a-syntrophin, however, caused ~1.5-fold increase in peak Na+ current and ~2.5-fold increase in 
persistent Na+ current [76], findings that are inconsistent with studies in cardiomyocytes and 
suggest cell type-specific regulatory mechanisms. Since the DGC complex is absent from the 
intercalated disc [227, 228], investigations of proteins that bound to the SIV motif at the this region 
revealed the interaction between NaV1.5 and SAP97 [229, 230]. Knock-down of SAP97 in cultured 
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rat atrial myocytes via shRNA reduced sodium current density by 66%, and reduced NaV1.5 
immunostaining in ventricular rat heart tissue [229]. Dependence of NaV1.5 expression on SAP97 
was later challenged in reports of unaffected NaV1.5 current and localization at the intercalated 
disc in SAP97 knockdown mice [231]. Again, differences in experimental models likely explain 
the discrepancy in results.  
 
Cell-attached macropatch recordings have offered further insights on the macromolecular 
interactions and compartment-specific functions of NaV1.5 at the lateral membrane and the 
intercalated disc. By placing electrodes and recording current from NaV1.5 channels specifically 
at the lateral membrane and intercalated disc, Lin et al showed that at the intercalated disc, NaV1.5 
peak current was significantly larger, steady-state inactivation was more depolarized, and recovery 
from inactivation was faster, indicating that action potential upstroke results mostly from NaV1.5 
at the intercalated disc rather than those at the lateral membrane [108]. Macropatch analysis of 
hearts of knock-in mutant mice that lacked the SIV domain (ΔSIV) showed about a ~62% 
reduction of peak current at the lateral membrane, while peak current was unaffected at the 
intercalated disc [104]. A ~60% decrease in NaV1.5 whole-cell current and reduction in channel 
immunostaining at the lateral membrane was also observed, indicating interaction of syntrophin 
with the SIV motif is required for partial expression of NaV1.5 at the lateral membrane. It was 
proposed that the remaining current at the lateral membrane originates from NaV1.5 channels at 
the T-tubules, although dystrophin and other DGC members are also expressed at the T-tubule 
[227, 232, 233]. Other explanations are that syntrophin is binding to the N-terminus in ΔSIV mice 
[234], or that a subset of NaV1.5 channels at the lateral membrane are independent of the DGC. 
These hypotheses were subsequently tested with a syntrophin knockdown mouse, where 
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macropatch experiments demonstrated a ~24% decrease in lateral membrane NaV1.5 current 
compared to control [105]. This decrease was not significantly different than macropatch currents 
at the lateral membrane in ΔSIV knock-in mice, suggesting the existence of NaV1.5 channels at 
the lateral membrane that are independent of syntrophin and the SIV motif. NaV1.5 expression was 
subsequently confirmed in the cardiomyocyte T-tubules by Vermij et al. using high-resolution 
single-molecule localization microscopy (SMLM). By quantifying colocalization of NaV1.5 with 
T-tubule marker Bin-1, Vermij et al. showed that T-tubular NaV1.5 expression is increased in 
cardiomyocytes from 16-week old Dmdmdx mice, although the functional effect of this sub-
compartment of NaV1.5 remains in question as this group showed that whole-cell NaV1.5 current 
was not different between control and detubulinated cells.  
 
3.2 Experimental Design and Approach 
Macromolecular complexes consisting of numerous proteins with specific roles are 
common and requisite functional units in cellular biology. Several techniques have been used in 
past studies to identify interactors and near-neighbors of NaV1.5, but there are several limitations 
to the approaches used. The most frequently used approach to identify these interacting proteins 
has been based upon hypothesis-driven immunoprecipitation or immunohistochemistry, but these 
types of experiments inevitably result in a biased view of the numbers and types of interactions 
that may exist [235]. Even among those directly interacting proteins, many interactions may have 
dissociation constants >10-100 μM and fast off-rate constants such that after cell lysis with 
detergents, detection by immunoprecipitation methods is impossible [236]. To identify proteins 
within spatially resolved and potentially weakly interacting multicomponent complexes as they 
occur in vivo, we have adapted the APEX2 proximity labeling method [179, 237, 238]. After 
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application of biotin-phenol for 30 minutes, then H2O2 for 1 minute, APEX2 catalyzes the 
oxidation of phenol to create highly reactive phenoxyl radicals that are capable of covalently 
labeling exposed Tyr residues and, to a lesser extent, other electron-rich amino acids [238]. 
Biotinylated proteins are purified and quantified using tandem mass tag synchronous precursor 
selection triple-stage mass spectrometry (TMT SPS MS3). The relative summed peptide TMT 
signal-to-noise ratio is used for relative protein quantification. We performed a two-tailed student’s 
T-test without correction to determine statistical significance. This approach was previously used 
to show the biologically relevant change of Rad in proximity of CaV1.2 α1C and β2 subunits [179]. 
We generated transgenic mice with doxycycline-inducible, cardiomyocyte-specific expression of 
NaV1.5 proteins with APEX2 and a V5 epitope conjugated to the N-terminus (V5-APEX2-NaV1.5) 
[208], enabling live-cell biotin-labeling of proteins within ~20 nm of the NaV1.5 subunit.  
 
We show that cells isolated from V5-APEX2-NaV1.5 are effective in labeling NaV1.5-
proximal proteins, including established NaV1.5 modulators as well as proximal bystanders likely 
encountered during V5-APEX2-NaV1.5 synthesis, maturation, and trafficking [208]. Although the 
comparison of samples labeled with the addition of H2O2 to no-label control samples without 
addition of H2O2 is useful for identifying proximal neighbors of NaV1.5, this approach is limited 
in the ability to reveal useful quantitative information on protein dynamics. Hundreds of proteins 
that are in proximity of V5-APEX2-NaV1.5 from genesis to degradation are labeled due to the 
complex molecular environment of the cell, making it difficult to distinguish bystanders from 
channel modulators.  The true potential the APEX2 proximity labeling is revealed in comparisons 
where a perturbation is made, such as after application of a drug or the study of a disease state. In 
this way, proteins unrelated to the studied process are normalized, reducing the amount of 
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significantly changing proteins to those that are directly affected by the perturbation. 
 
Here, we characterize of changes in the NaV1.5 macromolecular complex that result from 
DMD. Dystrophin-deficiency has been shown to have a profound effect on NaV1.5 function, but 
previous studies have largely described changes in NaV1.5 localization and function, rather than 
changes in the NaV1.5 macromolecular complex. Using native cardiomyocytes from Dmdmdx mice 
< 2 months of age, we describe the fundamental mechanisms that precede the exacerbated 
phenotype observed in aged Dmdmdx mice and human DMD patients. Our results portray a 
comprehensive view of alterations at the NaV1.5 interactome as well as global changes in protein 
expression, broadening our understanding of factors that affect NaV1.5 function. 
 
3.3 Results  
We adapted for application to cardiomyocytes the APEX2 proximity labeling method 
[237, 239], an approach we recently used to obtain a comprehensive proteome of CaV1.2 in 
cardiomyocytes [179]. We generated transgenic mice with doxycycline-inducible, 
cardiomyocyte-specific expression of V5-APEX2-NaV1.5. Fusing APEX2 to NaV1.5 did not 
affect NaV1.5 subcellular localization and function, as assessed by cellular electrophysiology and 
anti-V5 antibody immunofluorescence (Figure 1A). Incubating isolated ventricular 
cardiomyocytes from V5-APEX2-NaV1.5 mice with a solution containing biotin-phenol for 30 
minutes, then application of H2O2 for 1 minute induced robust biotinylation of proteins at the 
sarcolemma, at the intercalated disk, and in a striated z-disk pattern, coinciding with the pattern 





Figure 1. V5-APEX2-NaV1.5 traffics to the cardiomyocyte membrane. (A) Exemplar whole cell Na+ currents 
recorded from cardiomyocytes of TTX-sensitive NaV1.5-V5-APEX2 transgenic mice, before (black trace) and after 
(red trace) 20 nM TTX. Representative of 3 similar recordings. Vertical scale bar: 5 pA/pF; horizontal scale bar: 5 
ms. (B) Immunofluorescence of cardiomyocytes isolated from mice expressing NaV1.5-V5-APEX2 exposed to 
biotin-phenol and H2O2. Staining is with anti-V5– and –Alexa 594–conjugated secondary antibodies (upper) and 
streptavidin-conjugated Alexa 488. Scale bar: 5 μm. 
 
To probe for proteins that directly regulate NaV1.5, we isolated cardiomyocytes from 4 
V5-APEX2-NaV1.5 mice. The cells from each mouse were exposed to biotin-phenol and then 
were split into 2 aliquots: one population to be labeled with the addition of H2O2 and the other 
without addition of H2O2 to be used as a no-label control. We quantified biotinylated proteins 
using TMT SPS MS3. From the V5-APEX2-NaV1.5 control mice we identified and quantified 
hundreds of biotinylated proteins, including proteins known to localize to the three main NaV1.5 
subcellular domains in cardiomyocytes: the intercalated disk, T-tubule and Z-disk, and lateral 
membrane (Figure 2A). Several known NaV1.5 modulators were also identified. Many of the 
identified proteins are proximal bystanders rather than physically interacting with the channel, 
including the proteins of nearby organelles, such as subsarcolemmal mitochondria, which 
functionally couple with NaV1.5 channels [240], or proteins encountered during NaV1.5 
synthesis, maturation, and trafficking. Non-significantly changing proteins were categorized as 
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endoplasmic reticulum membrane (GO:0005789), organelle inner membrane (GO:0019866), and 
mitochondrial inner membrane (GO:0005743) proteins, demonstrating the relative specificity of 
V5-APEX2-NaV1.5 in enriching NaV1.5 interactors and near-neighbors. 
 
Figure 2. In situ biotin-labeling from V5-APEX2-NaV1.5 mice shows CaM and FGF13 in the NaV1.5 proteome. 
(A) Volcano plot showing differentially biotinylated proteins in V5-APEX2-NaV1.5 expressing cardiomyocytes 
compared to a no-labeling control. Data shown are means for four matching pairs of unlabeled and labeled sets of 
cardiomyocytes from four V5-APEX2 mice.  Proteins of the lateral membrane (blue), intercalated disk (magenta), T-
tubules (grey) and NaV1.5 modulators (orange) are highlighted. Non-adjusted unpaired two-tailed t-test. (B) 
Immunoblots of biotin-labeled proteins from cardiomyocytes of NaV1.5-APEX2 mice. NaV1.5, FGF13, and CaM are 
detected in streptavidin pull-down. Blots are representative of 2 independent experiments. 
 
Both NaV1.5 interactors discussed in the last chapter, CaM and FGF13, were among the 
proteins enriched by APEX proximity labeling and identified by TMT SPS MS3. As 
confirmation, we ran a western blot to show the biotinylation and streptavidin purification of 
both CaM and FGF13 (Figure 2B), confirming prior studies showing CaM and FGF13 interact 
with NaV1.5 [73, 198, 206, 241] and consistent with our results showing that CaM and FGF13 
modulate NaV1.5 function.  
 
After establishing the utility of V5-APEX2-NaV1.5 in identifying and quantifying proteins 
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in NaV1.5 macromolecular complexes, our next goal was to apply this approach to define 
alterations in the NaV1.5 interactome in the early stages of DMD. For all of our experiments, we 
limited our study to male mice < 2 months of age to avoid macromolecular complex alterations 
secondary to the dystrophic heart failure phenotype that is characteristic of aged Dmdmdx mice. 
Before performing proteomic analysis, we first applied whole-cell patch clamp analysis to 
understand the electrophysiologic phenotype of young Dmdmdx mice. The peak Na+ current in 
cardiomyocytes from Dmdmdx mice is reduced compared to control mice (Figure 3A), as was 
previously reported in mice 10-14 weeks old [103]. Contrasting with previous reports, we found 
that the V50 for steady-state inactivation is shifted by +3.2 mV, indicating that NaV1.5 availability 
is increased in young Dmdmdx mice (Figure 3B).  
 
Figure 3. Dystrophin-deficiency causes changes in NaV1.5 current in heart. (A) Sodium current-voltage 
relationship of 2-month-old WT and Dmdmdx mice.  n=22 for WT, 27 for Dmdmdx. P<0.0001 at -40 mV by two-tailed 
t-test. The peak sodium current, determined by whole-cell patch clamp, in cardiomyocytes from Dmdmdx mice is 
reduced compared to WT mice. (B) The V50 for steady-state inactivation is shifted by +3.2 mV. P<0.05 at V50 by 
two-tailed t-test. (C, E) Multi-channel record from WT and Dmdmdx myocytes shows rapid sodium channel 









pink shaded region for WT and Dmdmdx, respectively). Inset shows lone NaV1.5 opening to unitary current level 
(dashed line) in the late phase. Vertical scale bar = 10 pA, Horizontal scale bar = 100 ms. (D, F) Normalized 
ensemble-average open probability (Po) relation computed from 50-80 stochastic records. Inset shows low levels of 
late Po following 50 ms of depolarization. Vertical scale bar = 25% for normalized Po. (G) Extent of late sodium 
current (Po, late normalized to peak Po. Mean + SEM, P =non-significant (n.s.) by t-test. Loss of dystrophin did not 
increase late sodium current implying that loss of dystrophin did not affect the inactivation of NaV1.5 channels in 
cardiomyocytes. Multi-channel macropatch analysis performed with the assistance of Nourdine Chakouri and Manu 
Ben-Johny. 
 
It was previously reported that mutations in a-syntrophin caused a ~2.5-fold increase in 
INa,L in HEK293 cells [76]. To assess INa,L in Dmdmdx mice, we undertook cell-attached 
multichannel recordings to directly measure late channel openings [67, 203]. A 300 ms 
depolarizing pulse is used to elicit channel openings in cardiomyocytes from WT and Dmdmdx mice 
(Figure 3, C and E). Rapid activation followed by inactivation of multiple channels within the 
patch resulted in stacked channel openings reflecting near-macroscopic peak current. For channels 
from WT and Dmdmdx myocytes, we observed sparse late channel openings consistent with near-
complete inactivation. For each patch we obtained 50-80 stochastic traces to compute an ensemble 
average current, which was subsequently divided by the unitary current level to obtain NPo 
(channel number X open probability).  To determine late current, we normalized NPo trace by its 
peak value to obtain a normalized Po waveform for each patch (Figure 3, D and F) and computed 
the mean value following 50 ms of depolarization. Loss of dystrophin did not increase late Na+ 
current (Figure 3G) implying open-state inactivation of NaV1.5 channels is not affected in early 
stages of DMD.  
 
To elucidate the basis for the DMD-induced electrophysiological changes, we utilized 
previously-generated transgenic mice with doxycycline-inducible, cardiomyocyte-specific 
expression of V5-APEX2-NaV1.5 [208]. These mice were crossed with female Dmdmdx mice and, 
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because DMD is X-linked, we used only male mice for our studies. Isolated myocytes from 2-
month-old V5-APEX2-NaV1.5 control mice and V5-APEX2-NaV1.5-Dmdmdx mice were incubated 
with biotin-phenol before initiating labeling with H2O2. Western blots confirmed robust biotin-
tyramide conjugation of cardiac proteins (Figure 4A). We used dual anti-V5 antibody/Alexa594 
and streptavidin-Alexa488 fluorescence to detect localization of the transgenic NaV1.5 channels 
and the biotin-labeled NaV1.5 proteomic neighborhoods. V5 and streptavidin signals presented 
alike patterns in both control and Dmdmdx cardiomyocytes (Figure 4B), suggesting that the absence 
of dystrophin causes minimal effects on NaV1.5 subcellular localization. 
 
Figure 4. Biotin-labeling of cardiomyocyte proteins in NaV1.5-APEX mice. (A) Streptavidin-HRP blot after 
biotin-labeling of proteins in isolated ventricular cardiomyocytes. Lysates from V5-APEX2-NaV1.5 transgenic mice 
and V5-APEX2-NaV1.5-Dmdmdx were analyzed after proximity labeling (+H2O2) compared to no-labeling control (-
H2O2). (B) Immuno-fluorescence of cardiomyocytes isolated from WT (upper), V5-APEX2-NaV1.5 (middle) and 
V5-APEX2-NaV1.5-Dmdmdx (lower) mice exposed to biotin-phenol and H2O2. Staining is with anti-V5 and 
Alexa594-conjugated secondary antibodies (left), and streptavidin-conjugated Alexa488 (right). Nuclear labeling 
with DAPI stain. Scale bar = 5 µm. 
 
We isolated and labeled cardiomyocytes from five V5-APEX2-NaV1.5 mice and five V5-
APEX2-NaV1.5-Dmdmdx mice. These samples were combined in a TMT multiplex for subsequent 
mass spec analysis (Figure 5A). We identified and quantified 3.2 thousand biotinylated proteins 
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between the two groups, including proteins known to localize to the three main NaV1.5 subcellular 
domains in cardiomyocytes: the intercalated disc, T-tubule, and lateral membrane (Figure 5, B and 
C). Although there were several proteins that significantly changed in NaV1.5 proximity between 
Dmdmdx and non-diseased samples, it was unclear whether these alterations were due to recruitment 
or loss at the NaV1.5 subdomain (from either relocation of NaV1.5 or disease-responsive 
alterations) or if these alterations were reflective of the whole-cell changes in protein expression. 
To clarify this, we additionally quantified whole-cell protein lysates (not APEX2-biotinylated 
proteins) from V5-APEX2-NaV1.5 mice and V5-APEX2-NaV1.5-Dmdmdx mice. We identified and 
quantified 4.9 thousand proteins between the two groups (Figure 5D). 
 
As expected, a reduction in dystrophin by ~ 90% was observed in both the whole-cell and 
NaV1.5 subdomain proteomes. The abundance of several other members of the DGC (e.g., 
dystrobrevin, a1-syntrophin and sarcospan) were also similarly reduced [222]. The DGC member 
utrophin, which increased in abundance both globally and within the NaV1.5 neighborhood, was a 
notable exception (Figure 5, C and D) [102]. The compensatory increased expression of utrophin 
in mdx striated muscle is partially responsible for the reduced phenotype in murine vs. human 
DMD [242]. Our finding of increased utrophin within the NaV1.5 neighborhood is also consistent 
with utrophin functionally compensating for the absence of dystrophin. Importantly, these local 




Figure 5. Changes in the cellular and NaV1.5 subdomain proteome induced by dystrophin deficiency. (A) 
Schematic of workflow for isolated cardiomyocytes from V5-APEX2-NaV1.5 and V5-APEX2-NaV1.5-Dmdmdx mice. 
(B) Schematic depicting localization of V5-APEX2-NaV1.5 channels and regions of biotinylation at the intercalated 
disc, lateral membrane and T-tubules (created with Biorender.com). (C) Volcano plot of relative protein 
quantification of V5-APEX2-NaV1.5-Dmdmdx and V5-APEX2-NaV1.5 proximal proteome. Data shown are means 
for five pairs of biologically independent samples. Numbers in plot refer to known NaV1.5 modulators in the inset 
chart. High-ranked gene ontology (GO) terms for significantly changed proteins in the NaV1.5 subdomain proteome 
are color-coded.(D) Volcano plot of relative protein quantification by TMT mass spectrometry of V5-APEX2-
NaV1.5-Dmdmdx and V5-APEX2-NaV1.5 whole-cell proteome. N= 3 V5-APEX2-NaV1.5-Dmdmdx mice and 5 V5-
APEX2-NaV1.5 mice samples. Non-adjusted unpaired two-tailed t-test. High-rank gene ontology (GO) terms for 
significantly changed proteins in the whole-cell proteome are color-coded. 
 
In addition to the expected reduction in the DGC proteins within the NaV1.5 subdomain 
proteome of Dmdmdx mice cardiomyocytes, gene ontology (GO) analysis demonstrated the 
enrichment of ribosomal proteins (GO:0022626), focal adhesion proteins (GO:0005925) and 
proteasomal proteins (GO:0010499) (Figure 5C). The relative abundance of a substantial number 
of NaV1.5 modulators was unchanged in the NaV1.5 subdomain proteome of Dmdmdx 
cardiomyocytes compared to control cardiomyocytes, with some notable exceptions. We found a 
~22% reduction in protein tyrosine phosphatase H1 (Ptpn3), a ~18% reduction of glycerol 
A B
NaV1.5 Proximity Whole-CellC D
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phosphate dehydrogenase 1-like protein (Gdp1L), and a ~42% reduction of a1-syntrophin (Snta1). 
These significant values represent biologically relevant changes comparable to the ~30% decrease 
of Rad in proximity to CaVβ during β-adrenergic regulation of CaV1.2 [179]. Intriguingly, loss-of-
enzymatic-function mutations in Gdp1L, observed in both Brugada syndrome and sudden infant 
death syndrome, lead to increased PKC-dependent phosphorylation of NaV1.5 and reduced Na+ 
current [243]. Furthermore, decreased Ptpn3 activity causes a shift in the NaV1.5 availability 
towards depolarizing potentials [244]. Together these changes impact electrophysiology 
(decreased peak Na+ current and a depolarizing shift in availability) in parallel to those in 
dystrophin-deficient cardiomyocytes, hinting that the changes in NaV1.5 function in the Dmdmdx 
mice may be multifactorial.  
 
Our whole-cell dataset, obtained from young mice before the advent of heart failure, 
provide an informative contrast to a previous label-free mass spectrometric analysis of 20-month-
old dystrophin-deficient mice that found changes in the proteome indicative of impaired 
mitochondrial metabolism, altered Ca2+-handling, deficiencies in the basement membrane, 
fibrosis-related up-regulation of the extracellular matrix, and a heightened cellular stress response 
[245]. Some of these changes may have reflected secondary, end-stage processes that are 
characteristic of heart failure rather than dystrophin-deficiency-induced primary processes. 
Indeed, gene ontology (GO) analysis of the cardiomyocyte proteome of 2-month-old Dmdmdx mice 
showed limited evidence for deficiencies in the basement membrane, fibrosis-related up-regulation 
of the extracellular matrix, or a heightened cellular stress response. Rather, the proteome of the 2-
month-old Dmdmdx mice was marked by an enrichment of focal adhesion proteins (GO:0005925) 
and microtubule cytoskeleton proteins (GO:0015630), and depletion of mitochondrial and 
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metabolic proteins (GO:0005739) (Figure 5D). These changes in the cardiomyocyte proteome of 
2-month-old mice indicate that substantial alterations in metabolism presage the development of 
heart failure in older Dmdmdx mice [246]. Notable significant whole-cell changes include CaM 
(Calm1), which was significantly reduced by ~70% globally but non-significantly reduced locally, 
and N-cadherin (Cdh2), which was significantly reduced by ~41% globally, but unchanged locally 
in the Dmdmdx mice compared to control mice (Figure 5, C and D). These examples highlight the 
importance of parallel acquisition of whole-cell and local proteomic datasets and suggest a 
recruitment to the NaV1.5 subdomain of CaM, thereby attenuating late current [72] as we observed 
in our Dmdmdx macropatch experiments, and N-cadherin, which is proposed to enhance 
adhesion/excitability nodes at intercalated disks [247].  
 
We then queried whether changes in the NaV1.5 interactome within Dmdmdx mice 
cardiomyocytes reflected overall changes in the cardiomyocyte proteome or indicated specific 
changes to the NaV1.5 interactome. In general, for the proteins showing a significant change in 
abundance within the NaV1.5 domain proteome, Dmdmdx-induced changes in local NaV1.5 
neighborhood and the whole-cell proteome were highly correlated and the relationship was well-
fit (slope = 1.05) using linear regression, nearly overlapping with the line of identity (Figure 6A). 
Thus, changes to the NaV1.5 interactome, including focal adhesion and proteasomal proteins, 
generally reflect overall cellular changes due to loss of dystrophin. A notable exception, however, 
was that several large and small ribosomal subunit proteins were substantially enriched in the 




Figure 6. Comparison of Dmdmdx proximity and whole-cell changes. (A) Graph showing relationship of 
dystrophin-deficiency induced changes in whole-cell proteome vs. changes within the NaV1.5 subdomain for 
significantly changed proteins within the proximity of NaV1.5. Linear regression fit (black line) and line of unity 
(red line) shown. Proteins above dashed line at Y=1 are significantly enriched in the Dmdmdx NaV1.5 complex. (B) 
Graph showing relationship of dystrophin-deficiency induced changes in whole-cell proteome vs. changes within the 
NaV1.5 proximity for proteins principally localized to the lateral membrane, intercalated disk, and T-tubule. 
Overlapping linear regression fit (black line) and line of unity (dashed red line) shown. (C) The localization index, 
L, was calculated as a ratio of dystrophin-induced changes in NaV1.5 subdomain as measured by proximity 
proteomics (“APEX”) and dystrophin-induced changes in whole cell proteome (“WC”). These ratios are not 
significantly different (P = 0.73, ANOVA), implying that at early stages, dystrophin-deficiency does not cause 
redistribution of NaV1.5 channels in cardiomyocytes. 
 
Previous studies suggested that loss of dystrophin in Dmdmdx cardiomyocytes and the 
consequent reduction in syntrophin led to redistribution of NaV1.5 away from the lateral membrane 
[229], although later studies have suggested the existance of NaV1.5 channels at the lateral 
membrane with membrane expression independent of syntrophin interation [105, 106]. To further 
characterize the location of NaV1.5 in 2 week-old Dmdmdx mice, we leveraged the neighborhood-
specificity of proteins at the lateral membrane, intercalated disk, and T-tubules of cardiomyocytes. 
We devised a DMD-induced “localization index”, L, defined as the ratio of local-to-global 
abundance of a specific protein to triangulate the subcellular localization of NaV1.5 in 
cardiomyocytes based upon the identified neighbors. For instance, if dystrophin-deficiency 
induced changes in the local environment of NaV1.5 channels such that the channels were depleted 
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from the lateral membrane, as was previously reported for Dmdmdx mice [104, 229], the 
macromolecular complexes of NaV1.5 channels would be biased towards proteins specific to the 
intercalated disk and T-tubule and depleted of lateral membrane-specific proteins and L would be 
< 1 for lateral membrane proteins. We identified subsets of proteins within the NaV1.5 interactome 
and enriched for the distinct NaV1.5 subcellular locations, and then calculated L for each protein 
and an average L for the location-enriched subset (Figure 6, B and C). At the lateral membrane, 
dystrophin-deficiency-induced changes in both the global and local abundance of most proteins 
were, for the most part, congruent, reflected by mean L of 1.08 for 17 proteins known to principally 
localize to the lateral membrane of cardiomyocytes. Similarly, the mean L was 1.05 for 16 proteins 
known to localize principally to the intercalated disk, and 1.0 for proteins known to localize 
principally to T-tubules. Together, these data imply that the subcellular distribution of NaV1.5 
channels is not substantially changed in Dmdmdx cardiomyocytes. Nevertheless, individual outliers 
suggest some subtle changes to the NaV1.5 interactome in Dmdmdx mice cardiomyocytes, perhaps 
reflecting the remodeled DGC. Within the lateral membrane neighborhood, L increased for b and 
g-sarcoglycan, indicating that these proteins have greater accessibility to V5-APEX2-NaV1.5, and 
perhaps are closer to NaV1.5 channels in Dmdmdx mice. Within the intercalated disc associated 
neighbors, N-cadherin (Cdh2) was also an exception (L=1.62), as explained above. 
 
3.4 Discussion 
Taken together, our findings reveal insights in NaV1.5 macromolecular complex 
remodeling in a disease state. Our results comparing labeled V5-APEX2-NaV1.5 samples to an 
unlabeled control revealed proteins that are localized to the three NaV1.5 subcellular compartments 
at the lateral membrane, the intercalated disc, and the T-tubule. We also identified several known 
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NaV1.5 interactors including CaM and FGF13. The main findings exhibited in this chapter focus 
on the proteomic alterations of NaV1.5 in dystrophin-deficient Dmdmdx cardiomyocytes, a cellular 
model for Duchenne muscular dystrophy. We identified novel and known effects of dystrophin-
deficiency on protein dynamics in the NaV1.5 macromolecular complex as well as at the whole-
cell level. We additionally used proximity proteomics to conclude that at an early stage of muscular 
dystrophy in mice, before heart failure has developed, NaV1.5 channels localize with interacting 
proteins at the lateral membrane, T-tubule, and intercalated disc compartments in cardiomyocytes. 
This is in agreement with the hypothesis that the expression of some NaV1.5 channels at the lateral 
membrane are not dependent of an intact DGC [105, 106]. While our findings confirm prior reports 
demonstrating that the NaV1.5 macromolecular complex is altered in Dmdmdx mice, our data do 
not reveal a significant redistribution among the key NaV1.5 neighborhoods. Our results are novel 
in the use of quantitative TMT for cardiac mdx proteomic analysis and the application of proximity 
proteomics in a disease state mouse model.  
 
Proteins related to focal adhesion, ribosomes, and proteasomal degradation are enriched in 
the NaV1.5 neighborhood in the V5-APEX2-NaV1.5-Dmdmdx mice. These results can be interpreted 
in several ways. In cardiomyocytes, costameres are Z-line-associated structures that transmit 
contractile forces generated within the cardiomyocyte directly to the surrounding ECM [248]. 
There are two major protein complexes have been described at the costamere: the DGC and the 
integrin–vinculin–talin complex (IVTC), both of which play mechanical stabilizing and signaling 
roles in mediating interactions between the cytoskeleton, membrane, and extracellular matrix [221, 
249]. The IVTC is analogous to the focal adhesion complex present in in non-muscle cells and it 
has been shown that almost all the same proteins that comprise the IVTC eventually reassemble 
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within focal adhesions cultured cardiomyocytes [250, 251]. It is likely that the proteins that were 
categorized as focal adhesion in our gene ontology analysis (GO:0005925) are actually proteins of 
the IVTC. Interestingly, it’s been demonstrated that focal adhesion proteins in skeletal muscle are 
upregulated in dystrophin-deficient mice and protect against sarcolemmal damage [252, 253]. Our 
observations indicate that proteins of the IVTC may be upregulated at the costamere to compensate 
for the disrupted DGC observed in Dmdmdx mice. Furthermore, relocation of ribosomes to focal 
adhesion complexes is dependent on complex mechanical coupling to ECM, perhaps explaining 
the dual increase of focal adhesion and ribosomal proteins in the Dmdmdx NaV1.5 environment, 
although these prior observations were made in non-muscle cell types [254, 255]. At the 
intercalated disc of the cardiomyocyte, enrichment of transcripts and translational machinery has 
been shown to increase upon hypertrophic stimulation [256]. The specific function of many of the 
significant ribosomal proteins recovered in our results is not known, although Rps6 regulates pro-
survival ribosomal signaling [257]. The increased abundance of proteasomal proteins along with 
the reduced NaV1.5 current in Dmdmdx mice cardiomyocytes is consistent with a previous report 
that proteasomal degradation reduces NaV1.5 protein levels and Na+ current in dystrophin-deficient 
cardiomyocytes [258]. Dual increases in ribosomal and proteasomal proteins could be reflective 
of increased rates of protein synthesis and degradation in Dmdmdx mice [259]. Future work in 
determining the effect of increased proximity of ribosomal and proteasomal proteins on NaV1.5 
functions may lead to therapeutic insights. 
 
Our whole-cell proteomic results show enrichment of microtubule cytoskeleton proteins 
and focal adhesion proteins, and reduction of mitochondrial and metabolic proteins in our model 
for the 2-month-old Dmdmdx mice. Differential expression patterns of mitochondrial and metabolic 
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proteins were previously described in 20-month-old dystrophin-deficient mice, although it was 
unclear if this was causal or adaptive [220, 245]. By using mice < 2 months of age and minimizing 
involvement of cell death, fibrosis, and heart failure, our results suggest that an altered 
mitochondrial redox state precedes these events in increasing intracellular ROS that is known to 
contribute to the development of DMD [126, 260, 261]. The whole-cell proteomic results 
additionally align with reports detailing a denser and disorganized microtubule cytoskeleton 
described in dystrophin-deficient muscle [129, 130]. Of note, NaV1.5 traffics to the cell membrane 
via microtubules and preferentially localizes to the N-cadherin-rich area composita, a process that 
is dependent on connexin-microtubule interaction at the intercalated disc [91, 262]. Interestingly, 
movement of connexin-43 from the intercalated disc to the lateral membrane has been described 
in Dmdmdx mice, likely resulting from a disorganized microtubule network [131, 263]. Our studies 
show no significant whole-cell alterations in expression nor changes in NaV1.5 proximity of 
connexin-43, and our APEX2 assay is not suitable to assess connexin-43 lateralization. N-
cadherin, though, is significantly decreased at the whole-cell level but proximity to NaV1.5 is 
unchanged, perhaps reflecting the presence of compensatory mechanisms that crucially preserve 
NaV1.5 expression at the intercalated disc in the setting of altered connexin-microtubule 
interaction.  
 
We found that many proteins that have previously been shown to modulate NaV1.5 do not 
significantly change in proximity to NaV1.5 between control and Dmdmdx samples, with the 
exception of dystrophin, syntrophin, Gpd1l, and Ptpn3. Dystrophin and syntrophin were expected 
to decrease at the global and proximal level and it was previously hypothesized that loss NaV1.5 
interaction with these proteins results in a decrease in lateral membrane expression and concurrent 
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decrease in Na+ current [103]. Our results showing a proximal decrease in Gpd1l and Ptpn3, a 
decrease in NaV1.5 peak current, and a significantly right-shifted steady-state inactivation indicate 
that NaV1.5 disfunction in Dmdmdx might be multifactorial. Loss-of-enzymatic mutations in Gpd1l 
attenuate peak Na+ current in heterologous expression systems and neonatal mouse myocytes [264, 
265], resulting from increased PKC phosphorylation of NaV1.5 [243]. For future experiments, we 
plan on applying a PKC inhibitor to cardiomyocytes isolated from Dmdmdx mice and measuring 
peak Na+ current. It is also possible that other proteins that regulate NaV1.5 might be 
phosphorylated by the GPd1l pathway. For Ptpn3, loss-of-enzymatic mutations were shown to 
shift the voltage dependence of NaV1.5 steady-state inactivation in a depolarized direction [244]. 
Ptpn3 is hypothesized to counter Tyr phosphorylation of NaV1.5 by Fyn kinase and is dependent 
on the C-terminal SIV motif on NaV1.5. Similar to experiments on Gpd1l, we are planning on 
applying a Tyr phosphatase inhibitor to Dmdmdx cardiomyocytes to determine if reversal of the 
shift in steady-state inactivation occurs. Mass spectrometry phosphoproteomic analysis will also 
be important for determining if NaV1.5 is differentially phosphorylated in Dmdmdx cardiomyocytes. 
Finally, interaction of least four proteins (syntrophin, SAP97, CASK, and Ptpn3) with NaV1.5 is 
dependent or influenced by the SIV motif, and knock-in mice lacking the SIV domain (ΔSIV) 
showed reduced NaV1.5 expression by ~25% and Na+ current by ~37% [104]. Future studies using 
proximity proteomics can elucidate the mechanisms behind the ΔSIV phenotype, while also 
revealing information on site-specificity and macromolecular complex components of different 
NaV1.5 pools. 
 
Although our inducible APEX2 proximity labeling method is a powerful technique for 
identifying specially resolved transient interactions, there are limitations to our approach. 
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Doxycycline-inducible transgenic overexpression of NaV1.5 might not represent endogenous 
placement of NaV1.5 at different subcellular compartments in the cardiomyocyte. The use of H2O2 
for labeling also raises concern about potential oxidative stress and perturbation of cellular 
processes, although it was recently shown that addition of H2O2 for 1 minute did not statistically 
change quantification of proteins or post-translational modifications in iPSC-neurons [266]. 
Finally, the presence of thousands of proteins recovered in our proteomic analysis hinders robust 
analysis of relevant alterations and underscores the necessity for orthogonal validation. In order to 
address these limitations, we have generated a knock-in V5-TurboID-NaV1.5 mouse model. 
TurboID is a biotin ligase that only requires the addition of non-toxic exogenous biotin for 
proximal labeling [113]. In our knock-in mouse, V5-TurboID-NaV1.5 is expressed under the 
control of the wildtype gene regulatory elements, leading to expression of the transcript at 
endogenous levels. The labeling radius of TurboID is more restrictive than that of APEX2 and will 
provide a specific validation approach for our V5-APEX2-NaV1.5 results. Western blot analysis 
of cardiomyocytes isolated from homozygous knock-in mice treated with biotin shows robust 




Figure 7. In situ V5-TurboID-NaV1.5 expresses and labels proteins. (A) Anti-V5 western blot of lysates from 
V5-TurboID-NaV1.5 and V5-APEX2-NaV1.5  transgenic mice and wild-type (WT) control. (B) Streptavidin-HRP 
blot after biotin-labeling of proteins in isolated ventricular cardiomyocytes. Lysates from V5-TurboID-NaV1.5 
transgenic mice and WT control. 
 
3.5 Conclusion 
Evidence linking alterations of NaV1.5 voltage-gated Na+ channel function to arrhythmias 
or cardiomyopathy in the absence of NaV1.5 mutations underscores the need to decode the protein 
components within NaV1.5 macromolecular complexes. Prior studies offered only a superficial 
view of the NaV1.5 interactome, thus limiting insights into disease-related NaV1.5 dysfunction that 
is independent of mutations in NaV1.5. Here, we apply proximity labeling and multiplexed 
quantitative proteomics approaches to define the NaV1.5 macromolecular complex in the healthy 
murine heart. Additionally, we identified alterations in the early stages of DMD, in which the 
absence of dystrophin predisposes affected individuals to arrhythmias and cardiac dysfunction. 




























profile and to place context behind NaV1.5-proximal changes. Finally, we leveraged the 
neighborhood-specificity of proteins at the lateral membrane, intercalated disc, and T-tubules of 
cardiomyocytes to demonstrate that NaV1.5 channels can traffic to all three membrane 
compartments even in the absence of dystrophin, contrary to previous reports. Thus, the approach 
of proximity labeling in cardiomyocytes from an animal model of human disease offers new 
insights into molecular mechanisms of NaV1.5 dysfunction in DMD and provides a framework for 



















 Ionic currents were studied in fine detail by Alan Hodgekin and Andrew Huxely in 1952, 
and it was subsequently shown that these currents were mediated by selective ion channels. 
Since these discoveries, the critical role of ion channels for normal physiologic function has been 
extensively demonstrated. CaV1.2 and NaV1.5 each contribute to the cardiac action potential, 
rapidly initiating the steep upstroke in phase 0 and balancing K+ efflux to form the phase 2 
plateau, respectively. Functional defects in these channels can occur at any level— from 
mutations in the genome to altered interactions with enzymes and proteins that modulate the 
biophysical activity of the channel. Perturbations in channel modulation have been shown to 
result in electrophysiological and structural disease of the heart. For this reason, understanding 
the mechanisms and effects of channel modulation is essential for therapy development.  
 
In Chapter 1, we investigated whether the α1C subunit and β2 subunit of CaV1.2 are the 
functional PKA phosphorylation targets for β-adrenergic regulation of CaV1.2. Increased 
Ca2+ entry into the myocytes via CaV1.2, mediated by both β1- and β2-adrenergic receptors, 
substantially contributes to the positive inotropic effect of β-adrenergic activation. Dozens of 
past studies have supported and ruled out putative PKA phosphorylation sites on the α1C and β2 
subunits, complicating the search and leading to no consensus answer. After mutating all 
putative and predicted PKA phosphorylation sites on the α1C and β2 subunits, then co-expressing 
the mutated subunits, we showed that β-adrenergic regulation of CaV1.2 was unaltered. This 
provided the definitive answer that neither subunit is the functional PKA phosphorylation site. 
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These results were the basis for later studies revealing that the Ca2+ channel inhibitor Rad is the 
functional PKA phosphorylation target, a finding that was supported by our demonstration of 
intact β-adrenergic regulation of CaV1.2 after heterologous coexpression of Rad with mutant 
CaV1.2 subunits.  
 
In Chapter 2, we characterized the disruption of CaM binding to the IQ region on the 
NaV1.5 C-terminus in cardiomyocytes. The C-terminus is a hotspot for mutations identified in 
patients with LQT3, which can be caused by an increase in INa,L. Coexpression of NaV1.5 
channels mutated at the IQ region (IQ/AA) with CaM in heterologous expression systems causes 
increased INa,L, leading to the hypothesis that mutations that abrogate the CaM-NaV1.5 
interaction in cardiomyocytes also increase INa,L and are the basis for the observed QT interval 
prolongation in LQT patients. Surprisingly, we found no differences in INa,L between 
cardiomyocytes expressing wild-type NaV1.5 and those expressing mutant IQ/AA NaV1.5. Since 
prior studies have demonstrated that FGF13 modulates INa,L, we tested the ability of FGF13 to 
rescue the late current phenotype of IQ/AA channels in HEK293 cells. After confirming prior 
studies showing increased INa,L in HEK293 cells expressing IQ/AA channels, we showed that 
additional coexpression of FGF13 significantly ablated INa,L. We conclude that FGF13 serves as 
an endogenous protective mechanism in cardiomyocytes that counteracts the increase in INa,L 
after loss of CaM binding.  
 
In Chapter 3, we applied proximity proteomics to describe changes in the NaV1.5 
macromolecular complex as they occur in living cardiomyocytes. Previous studies of NaV1.5 in 
dystrophin-deficient Dmdmdx cardiomyocytes showed a decrease in Na+ current and a loss of Na+ 
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channels specifically from the lateral membrane of the cardiomyocyte, but failed to completely 
describe alterations of interactions between NaV1.5 and modulating proteins. To do this, we 
expressed NaV1.5 fused to APEX2 in Dmdmdx mice and isolated cardiomyocytes when mice were 
< 2 months of age in order to minimize the effects of dystrophic cardiomyopathy. We first 
showed that Na+ current was decreased and voltage-dependence of steady-state inactivation was 
significantly depolarized in young Dmdmdx mice compared to wild-type control mice. Our 
proteomic analysis revealed changes in the NaV1.5 macromolecular complex that partially 
accounted for these changes, including a decrease in Ptpn3 and Gdp1l and an increase in 
proteasomal machinery. Finally, we quantified whole-cell proteomic changes and used these 
values to define a “localization index” that described the changes in the proximity of subcellular 
location-specific neighbors of NaV1.5. Localization index values were used to show that NaV1.5 
traffics to the intercalated disk, T-tubules, and lateral membrane of the cardiomyocyte. 
Altogether, our results provide in-depth details on the regulation of Ca2+ and Na+ channels of the 
heart by enzymes and direct modulators. These mechanistic insights represent a step toward the 
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